Compound used as kinase inhibitor and application thereof

By developing compounds with inhibitory activity against EGFR and Her2 exon 20 insertion mutations, the problem of poor efficacy of existing drugs has been solved, providing an effective treatment option for EGFR and Her2 mutant tumors.

CN119019383APending Publication Date: 2024-11-26TYK MEDICINES ZHENGZHOU INC +1
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202411130331.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2020-03-13
Filing Date
2021-03-15
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Existing drugs are not very effective against EGFR and Her2 exon 20 insertion mutations, especially EGFR exon 20 insertion mutations, with a clinical response rate of only about 40%, which fails to meet clinical needs.

Method used

A class of compounds has been developed that are kinase inhibitors with good inhibitory activity against EGFR, Her2 exon 20 insertion mutations, EGFR exon 19 deletions, and L858R point mutations in exon 21, for use in the preparation of drugs to treat related diseases.

Benefits of technology

These compounds have a significant inhibitory effect on EGFR and Her2 exon 20 insertion mutations, and have great potential to become effective drugs for treating related diseases, especially tumors caused by EGFR and Her2 mutations.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004997633450000021
    Figure BDA0004997633450000021
  • Figure BDA0004997633450000022
    Figure BDA0004997633450000022
  • Figure BDA0004997633450000023
    Figure BDA0004997633450000023
Patent Text Reader

Abstract

The invention relates to a compound used as a kinase inhibitor and application thereof, and belongs to the technical field of medicines. The compounds used as kinase inhibitors have good inhibitory activity on insertion mutation of EGFR and Her2 exon 20, deletion of EGFR exon 19 and L858R point mutation of exon 21, and have great potential to be developed into drugs for treating related diseases.
Need to check novelty before this filing date? Find Prior Art

Description

This application is a divisional application of the following application. The application date of the original application is 2021.03.15, the application number of the original application is 202180013936.6, and the patent name of the original application is: A class of compounds used as kinase inhibitors and their applications. Technical Field

[0001] The invention relates to a class of compounds used as kinase inhibitors and applications thereof, belonging to the technical field of medicines. Background Art

[0002] The epidermal growth factor receptor belongs to the receptor tyrosine kinase (RTK) family, which includes EGFR / ERBB1, HER2 / ERBB2 / NEU, HER3 / ERBB3 and HER4 / ERBB4. The epidermal growth factor receptor activates its tyrosine kinase activity through homodimerization or heterodimerization, and then phosphorylates its substrate, thereby activating multiple downstream pathways related to it in the cell, such as the PI3K-AKT-mTOR pathway involved in cell survival and the RAS-RAF-MEK-ERK pathway involved in cell proliferation. Mutations or amplifications of the epidermal growth factor receptor will lead to the activation of the epidermal growth factor receptor kinase, leading to the occurrence of various human diseases, such as malignant tumors. For example, in patients with non-small cell lung cancer, about 10% of American patients have EGFR mutations, while the proportion of patients with EGFR mutations in Asian patients can reach nearly 50%. At the same time, the incidence of Her2 mutations in patients with non-small cell lung cancer is about 2-4%.

[0003] EGFR mutations mainly include deletions, insertions, and point mutations, among which exon 19 deletions and exon 21 L858R point mutations account for nearly 90% of EGFR mutations. For patients with tumors with these EGFR mutations, the EGFR-TKIs currently on the market include first-generation Iressa, Tarceva, and Conmena, second-generation afatinib and dacomitinib, and third-generation osimertinib. The other 10% of EGFR mutations mainly involve exons 18 and 20 of EGFR, and the insertion mutation of EGFR exon 20 accounts for about 9% of the entire EGFR mutation. For patients with tumors with Her2 mutations, the most common Her2 mutation is the insertion mutation of Her2 exon 20. There is currently no drug on the market for exon 20 insertion mutations of EGFR and Her2.

[0004] Recently, it has been reported that TAK-788 has a certain activity against clinical EGFR exon 20 insertion mutations. From the reported clinical trial results, the clinical response rate is only about 40%, and the efficacy is not satisfactory. Currently, this compound is still under clinical research. Summary of the invention

[0005] In order to meet the drug needs of patients with EGFR and Her2 mutations, especially those with EGFR and Her2 exon 20 insertion mutations, the present invention has developed a series of compounds with excellent EGFR and Her2 exon 20 insertion mutation activity and EGFR exon 19 deletion and exon 21 L858R point mutation, which have great potential to be developed into drugs for the treatment of related diseases.

[0006] The first object of the present invention is to provide a class of compounds used as kinase inhibitors, which have good inhibitory activity against EGFR, Her2 exon 20 insertion mutation, EGFR exon 19 deletion and exon 21 L858R point mutation.

[0007] The second object of the present invention is to provide the use of the above-mentioned compound in the preparation of a drug for treating related diseases caused by EGFR mutation and / or Her2 mutation.

[0008] To solve the above problems, the technical solution adopted by the compound used as a kinase inhibitor of the present invention is:

[0009] A class of compounds used as kinase inhibitors is a compound as shown in Formula I or a pharmaceutically acceptable salt, solvate or prodrug thereof:

[0010]

[0011] In Formula I, A is selected from:

[0012]

[0013] Among them, Z5, Z6, Z7, Z8, Z9, Z 11 and Z 12 Each independently selected from N and CR4; Z 10 Selected from R8 is selected from H, amino, ester, C 1-6 Alkyl, C 1-6 Deuterated alkyl radicals, C 1-6 Alkoxy, C 1-6 Deuterated alkoxyl groups, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, C 6-10 aryl, 5-10 membered heteroaryl, or amino, ester, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, C 6-10aryl, 5-10 membered heteroaryl; the 5-10 membered heteroaryl contains at least one heteroatom, the heteroatom is selected from N, O, S or P; m is 0, 1, 2 or 3; C is selected from a 4-7 membered ring;

[0014] Z1 and Z2 are each independently selected from N or CR4;

[0015] L is selected from a single bond, or

[0016] B is selected from C 6-10 aryl, 5-10 membered heteroaryl, C substituted by 1 to 3 substituents 6-10 aryl, 5-10 membered heteroaryl substituted by 1-3 substituents; the substituents are each independently selected from H, halogen, cyano, amino, ester, urea, carbamate, amide, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, C 1-6 Alkylamino, C 3-12 Cycloalkylamino, C 1-6 The halogenated alkyl, C 1-6 The haloalkoxy, C 3-6 The halogenated cycloalkyl, C 3-6 Halogenated cycloalkoxy, C 1-6 haloalkylamino, C 3-12 The halogenated cycloalkylamino, C 6-10 substituted with 1 to 3 R groups, aryl, 5-10 membered heteroaryl, or amino, ester, urea, carbamate, amide, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, C 1-6 Alkylamino, C 3-12 Cycloalkylamino, C 1-6 The halogenated alkyl, C 1-6 The haloalkoxy, C 3-6 The halogenated cycloalkyl, C 3-6 Halogenated cycloalkoxy, C 1-6 haloalkylamino, C 3-12 The halogenated cycloalkylamino, C 6-10 aryl, 5-10 membered heteroaryl;

[0017] The R groups are each independently selected from halogen, cyano, amino, hydroxyl, ester, urea, carbamate, amide, C 1-6 Alkyl, C 1-6 Alkoxy, C3-6 Cycloalkyl, C 3-6 Cycloalkoxy, C 1-12 Alkylamino, C 6-10 aryl, 5-10 membered heteroaryl, Wherein, Y1, Y2, Y3, Y4, and Y5 are each independently selected from hydrogen, halogen, C 1-12 Alkyl, C 3-12 Cycloalkyl, C 1-12 Alkylamino, R Y Selected from C 1-12 Alkyl, C 3-12 Cycloalkyl, C 1-12 A group formed by replacing one or more carbon atoms in the alkyl group with one or more heteroatoms such as N, O, or S. 3-12 A group formed by replacing one or more carbon atoms in the cycloalkyl group with one or more heteroatoms selected from N, O, and S;

[0018] R4, R6, R7, R9 and R 10 Each independently selected from H, halogen, cyano, amino, ester, sulfone, urea, carbamate, amide, phosphorus, 1-6 Alkyl, C 1-6 Deuterated alkyl radicals, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, C 6-10 aryl, 5-10 membered heteroaryl, 5-10 membered aliphatic heterocyclic group, or amino, ester, sulfone, urea, carbamate, amide, C substituted by 1 to 3 of the above R 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, C 6-10 aryl, 5-10 membered heteroaryl, 5-10 membered aliphatic heterocyclic group;

[0019] R5 is selected from H, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, C 6-10 aryl, 5-10 membered heteroaryl;

[0020] Wherein, when Z1, Z2 are selected from CH, A is selected from B is selected from C substituted by 1 to 3 substituents 6-10 substituted with 1 to 3 substituents, at least one of the 1 to 3 substituents in B is

[0021] The compound used as a kinase inhibitor provided by the present invention has good inhibitory activity against EGFR and Her2 exon 20 insertion mutations, EGFR exon 19 deletion and exon 21 L858R point mutation, and has great potential to be developed into a drug for treating related diseases.

[0022] In order to further optimize the inhibitory effect on EGFR and Her2 exon 20 insertion mutations, preferably, the compound used as a kinase inhibitor is a compound as shown in Formula II or a pharmaceutically acceptable salt, solvate or prodrug thereof:

[0023]

[0024] In the formula, Z3 and Z4 are each independently selected from N and CR4;

[0025] R1 and R2 are each independently selected from H, halogen, cyano, amino, ester, urea, carbamate, amide, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, C 1-6 Alkylamino, C 3-12 Cycloalkylamino, C 1-6 The halogenated alkyl, C 1-6 The haloalkoxy, C 3-6 The halogenated cycloalkyl, C 3-6 Halogenated cycloalkoxy, C 1-6 haloalkylamino, C 3-12 The halogenated cycloalkylamino, C 6-10 aryl, 5-10 membered heteroaryl, or amino, ester, urea, carbamate, amide, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, C 1-6 Alkylamino, C 3-12 Cycloalkylamino, C 1-6 The halogenated alkyl, C 1-6 The haloalkoxy, C 3-6 The halogenated cycloalkyl, C 3-6 Halogenated cycloalkoxy, C 1-6 haloalkylamino, C 3-12 The halogenated cycloalkylamino, C 6-10 aryl, 5-10 membered heteroaryl;

[0026] R3 is selected from Wherein, Y1, Y2, Y3, Y4, and Y5 are each independently selected from hydrogen, halogen, C 1-12 Alkyl, C 1-12 Alkoxy, C 3-12 Cycloalkyl, C 1-12 The alkylamino group, the R substituted C 1-12 of alkylamino.

[0027] To further optimize the inhibitory effect on EGFR and Her2 exon 20 insertion mutations, preferably, Z1 is CR4, Z2 is CH, wherein R4 is selected from H, a 5-9 membered heteroaromatic ring containing one or more nitrogen atoms, a heteroaromatic ring having 1-3 substituents R 12 5-9 membered heteroaryl containing one or more nitrogen atoms, cyano,

[0028] R 12 , R 13 Each independently selected from H, ester group, acyl group, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, C 6-10 aryl, 5-9 membered heteroaryl, or an ester group, acyl group, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, C 6-10 The invention also includes aryl and 5-9 membered heteroaryl.

[0029] To further optimize the inhibitory effect on EGFR and Her2 exon 20 insertion mutations, preferably, the compound is represented by formula III:

[0030]

[0031] In formula III, R8 is hydrogen, C 3-6 Cycloalkyl, C 1-3 Alkyl, C 1-3 Deuterated alkyl radicals, C 1-3 of a haloalkyl group;

[0032] R4 is selected from H, Among them, R 14 C 1-3 alkyl, n is an integer of 1-3, R 12 , R 13 , R 15 Each independently selected from H or C 1-3 The alkyl group;

[0033] Z3 and Z4 are each independently selected from CH or N;

[0034] R1 is selected from hydrogen, C 1-3 Alkoxy, C 1-3 The haloalkoxy, C 1-3 Deuterated alkoxyl groups, C 3-6 Cycloalkyl;

[0035] R2 is selected from Wherein, the D ring is a 4-6 membered cycloalkylamino group;

[0036] R3 is selected from

[0037] Wherein, when R4 is selected from When Z3 and Z4 select CH at the same time, R2 is selected from

[0038] When R4 is selected from H, R2 is selected from

[0039] Preferably, it is a compound represented by formula III':

[0040]

[0041] In formula III', R8 is hydrogen, C 3-6 Cycloalkyl, C 1-3 Alkyl, C 1-3 Deuterated alkyl radicals, C 1-3 of a haloalkyl group;

[0042] R4 is selected from Among them, R 14 C 1-3 alkyl, n is an integer of 1-3, R 12 , R 13 , R 15 Each independently selected from H or C 1-3 The alkyl group;

[0043] Z3 and Z4 are each independently selected from CH or N, and at least one of them is selected from N;

[0044] R1 is selected from hydrogen, C 1-3 Alkoxy, C 1-3 The haloalkoxy, C 1-3 Deuterated alkoxyl groups, C 3-6 Cycloalkyl;

[0045] R2 is selected from Wherein, the D ring is a 4-6 membered cycloalkylamino group;

[0046] R3 is selected from

[0047] In order to further optimize the inhibitory effect on EGFR and Her2 exon 20 insertion mutations, preferably, the compounds are represented by formula IV, formula V, formula VI, formula VII, formula VIII, and formula IX:

[0048]

[0049] In Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, and Formula IX, R1 is selected from hydrogen, C 1-3 Alkoxy, C 1-3 The haloalkoxy, C 1-3 Deuterated alkoxyl groups, C 3-6 Cycloalkyl;

[0050] R2 is selected from Wherein, the D ring is a 4-6 membered alkylamine ring;

[0051] R3 is selected from

[0052] R4 is selected from H, Among them, R 14 C 1-3 alkyl, n is an integer of 1-3, R 12 , R 13 , R 15 Each independently selected from H or C 1-3 The alkyl group;

[0053] R 16 Select from H or C 1-3 of alkyl.

[0054] In order to further optimize the inhibitory effect on EGFR and Her2 exon 20 insertion mutations, preferably, the structural formula of the compound used as a kinase inhibitor is selected from the following structures:

[0055]

[0056] The compound with the following structure has a good inhibitory effect on not only EGFR exon 20 insertion mutation, but also exon 19 deletion and exon 21 L858R point mutation.

[0057] Preferably, the above compound has a structure shown in Formula X:

[0058]

[0059] In formula X, R8 is selected from H, C 1-4 Alkyl, C 1-4 Deuterated alkyl radicals, C 1-4 of a haloalkyl group;

[0060] Y1, Y2, and Y3 are each independently selected from H, D, halogen, C 1-4 The halogenated alkyl, C 1-4 Deuterated alkyl, -CH2NR 111 R 112 or Wherein, the D ring is a 4-6-membered cycloalkylamino group or a 4-6-membered heterocycloalkylamino group, wherein 1-3 ring carbon atoms on the heterocycloalkylamino group are substituted by heteroatoms, and the heteroatoms are selected from O, S or N;

[0061] R4 is selected from Where R 40 Selected from H, C 1-4 Alkyl, or C 1-4 deuterated alkyl, or C 1-4 of a haloalkyl group;

[0062] R 11 Selected from Where R 110 , R 111 , R 112 Each independently selected from H, C 1-4 Alkyl, or C 1-4 deuterated alkyl, or C 1-4 of a haloalkyl group;

[0063] Among them, when R 11 Selected from Y1, Y2, and Y3 are all H, R8 is methyl, and R4 is When R 40 Selected from H, C 2-4 Alkyl, C 1-4 Deuterated alkyl or C 1-4 of a halogenated alkyl group.

[0064] More preferably, it is a compound represented by Formula XI or Formula XII:

[0065]

[0066] In Formula XI and Formula XII, R 11 Selected from

[0067] Preferably, it is a compound of the following structural formula:

[0068]

[0069] Preferably, it is a compound represented by formula X':

[0070]

[0071] In formula X', R8 is selected from H, C 1-4 Alkyl, C 1-4 Deuterated alkyl radicals, C 1-4 of a haloalkyl group;

[0072] Y1, Y2, and Y3 are each independently selected from H, D, halogen, C 1-4 The halogenated alkyl, C 1-4 Deuterated alkyl, -CH2NR 111 R 112 or Wherein, the D ring is a 4-6-membered cycloalkylamino group or a 4-6-membered heterocycloalkylamino group, wherein 1-3 ring carbon atoms on the heterocycloalkylamino group are substituted by heteroatoms, and the heteroatoms are selected from O, S or N;

[0073] R 11 Selected from Where R 110 , R 111 , R 112 Each independently selected from H, C 1-4 Alkyl, or C 1-4 deuterated alkyl, or C 1-4 of a halogenated alkyl group.

[0074] More preferably, it is a compound of the following structural formula:

[0075]

[0076] Unless otherwise specified, the following terms used in this specification and claims have the following meanings:

[0077] C 6-10 The aryl group is a monocyclic or bicyclic aromatic hydrocarbon group having 6 to 10 ring atoms, for example, phenyl or naphthyl.

[0078] 5-10 membered heteroaryl refers to a monocyclic or bicyclic aromatic group having 5 to 10 ring atoms, wherein one or more, preferably one, two or three, ring atoms are heteroatoms selected from N, O, S, and the remaining ring atoms are carbon. Representative examples include, but are not limited to, pyrrolyl, thienyl, thiazolyl, imidazolyl, furanyl, indolyl, isoindolyl, oxazolyl, isoxazolyl, benzothiazolyl, benzoxazolyl, quinolyl, isoquinolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl, tetrazolyl, and the like.

[0079] 5-10 membered aliphatic heterocyclyl refers to a monocyclic or bicyclic non-aromatic group having 5 to 10 ring atoms, wherein one or more, preferably one, two or three, of the ring atoms are heteroatoms selected from N, O, S, and the remaining ring atoms are carbon.

[0080] Alkylamino refers to a -NR'R" group, wherein R' and R" are selected from hydrogen or alkyl, and R' and R" are not hydrogen at the same time, for example, methylamino, ethylamino, propylamino, dimethylamino, diethylamino, ethylmethylamino, propylmethylamino, and the like.

[0081] Cycloalkylamino refers to a group having the following structure etc., wherein R is an alkyl group, m, n, m' and n' are each independently selected from 0, 1, 2, 3 or 4, but m and n are not 0 at the same time, and m' and n' are not 0 at the same time.

[0082] Phosphorus oxygen has The structural group, R 12 , R 13 The meaning of is as described above.

[0083] Haloalkyl, haloalkoxy, halocycloalkyl, halocycloalkoxy, haloalkylamino and halocycloalkylamino are groups formed by replacing hydrogen in corresponding groups such as alkyl with halogen, and the specific number of substitutions can be one or more.

[0084] The halogenated alkyl group may be monosubstituted, disubstituted or trisubstituted, and the preferred substituted halogen is fluorine. The number of deuterated alkyl groups may be one, two, three, ... or all.

[0085] Represents the location of chemical bonds.

[0086] The above compounds have been confirmed through biological activity experiments to have good inhibitory activity against EGFR and Her2 exon 20 insertion mutations, exon 19 deletions and L858R point mutations in exon 21, and can be used as the original drugs of related drugs.

[0087] Based on the above original drug, the "pharmaceutically acceptable salt" of the original drug refers to a salt that is pharmaceutically acceptable and has the desired pharmacological activity of the parent compound. Such salts include:

[0088] Acid addition salts formed with inorganic acids, such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid, etc., and typical inorganic acid salts are selected from hydrochloride, hydrobromide, hydroiodide, sulfate, hydrogensulfate, nitrate, phosphate, and acid phosphate. Acid addition salts formed with organic acids, such as formic acid, acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4- Toluenesulfonic acid, camphorsulfonic acid, glucoheptonic acid, 4,4'-methylenebis-(3-hydroxy 2-ene-1-carboxylic acid), 3-phenylpropionic acid, trimethylacetic acid, tert-butylacetic acid, dodecylsulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, etc.; or a salt formed by coordination of an acidic proton present in the parent compound with an organic base (e.g., ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucosamine, etc.). Typical organic acid salts are selected from formate, acetate, trifluoroacetate, propionate, pyruvate, glycolate, oxalate, malonate, fumarate, maleate, lactate, malate, citrate, tartrate, methanesulfonate, ethanesulfonate, isethionate, benzenesulfonate, salicylate, picrate, glutamate, ascorbate, camphorate, camphorsulfonate. It is easy to understand that the pharmaceutically acceptable salt is non-toxic.

[0089] Solvates are compounds containing a solvent, such as hydrates, dimethyl sulfoxides, and the like.

[0090] A prodrug is a compound that undergoes chemical transformation through metabolism or chemical processes to produce a compound, salt, or solvate of the present invention when used to treat a related disease.

[0091] The technical solution for the application of the above-mentioned compound of the present invention is:

[0092] Use of the above-mentioned compound used as a kinase inhibitor in the preparation of drugs for treating related diseases caused by EGFR mutation and / or Her2 mutation.

[0093] Based on the good inhibitory activity of the above compounds against exon 20 insertion mutations of EGFR and Her2, and the expected good inhibitory activity against EGFR exon 19 deletion and L858R point mutation of exon 21, drugs based on the above compounds are expected to have good therapeutic effects on related diseases.

[0094] Preferably, the EGFR mutation and / or Her2 mutation is exon 20 insertion mutation, EGFR exon 19 deletion, L858R point mutation of EGFR exon 21. Biological activity experiments have confirmed that the above compounds have a good inhibitory effect on the above mutation types of exon 20 of the above two kinases.

[0095] The above compounds can also be used in combination with other drugs for the treatment of cancer. Other drugs used in combination can be ERK inhibitors or MEK inhibitors. The cancer is preferably lung cancer, and more preferably lung cancer caused by EGFR and Her2 exon 20 insertion mutations and EGFR exon 19 deletion and exon 21 L858R point mutation. DETAILED DESCRIPTION

[0096] The technical solution of the present invention is further described below, but the protection scope of the present invention is not limited thereto. It mainly includes a chemical experiment part and a biological experiment part.

[0097] 1. Chemical Experiment Section

[0098] 1. The intermediates involved in the examples are described below.

[0099] Intermediate 1

[0100] Synthesis route:

[0101]

[0102] Indole (20 g, 170.9 mmol), iodomethane (48.5 g, 341.8 mmol) and cesium carbonate (111 g, 341.8 mmol) were added to N,N-dimethylformamide and reacted at room temperature for 16 h, monitored by TLC. After the reaction of the raw materials, water and ethyl acetate were added to the reaction system, the aqueous phase was extracted three times, dried by spin drying, and purified by column to obtain 22 g of the product. 1H NMR (400MHz, CDCl3) δ7.62(dt,J=8.0,1.2Hz,1H),7.29(dt,J=8.0,1.2Hz,1H),7.21(ddd,J=8.0,6.8,1.2H z,1H),7.10(ddd,J=8.0,6.8,1.2Hz,1H),7.00(d,J=3.2Hz,1H),6.47(dd,J=3.2,0.8Hz,1H),3.72(s,3H).

[0103] Intermediate 2

[0104] Synthesis route:

[0105]

[0106] Indole (5 g, 42.7 mmol), deuterated iodomethane (9.3 g, 64.1 mmol) and cesium carbonate (21 g, 64.6 mmol) were added to N,N-dimethylformamide and reacted at room temperature for 16 h, monitored by TLC. After the reaction of the raw materials, water and ethyl acetate were added to the reaction system, the aqueous phase was extracted three times, dried by spin drying, and purified by column to obtain 5.3 g of product. 1 H NMR (400MHz, CDCl3) δ7.63 (dq, J=8.1, 1.1Hz, 1H), 7.27 (dt, J=8.2, 1.0Hz, 1H), 7.21 (ddd, J=8.3, 6. 8,1.2Hz,1H),7.11(ddd,J=8.2,6.8,1.2Hz,1H),6.97(d,J=3.1Hz,1H),6.47(dd,J=3.0,1.3Hz,1H).

[0107] Intermediate 3

[0108] Synthesis route:

[0109]

[0110] Indole (5.3 g, 45.3 mmol), cyclopropane bromide (9.8 g, 81.5 mmol) and potassium hydroxide (5.4 g, 81.5 mmol) were added to N,N-dimethylformamide and reacted at 0°C for 2 h, monitored by TLC. After the reaction of the raw materials, ice water and ethyl acetate were added to the reaction system, the aqueous phase was extracted three times, dried by spin drying, and purified by column to obtain 2.8 g of the product.

[0111] Intermediate 4

[0112] Synthesis route:

[0113]

[0114] Synthesis of compound 2: Compound 1 (20 g, 107.5 mmol) and DMAP (2.62 g, 21.5 mmol) were dissolved in dichloromethane, cooled to 0°C under nitrogen protection, and then a dichloromethane solution of Boc2O (25.78 g, 118.2 mmol) was slowly added dropwise. After the addition was completed, the temperature was raised to room temperature and the reaction was continued for 16 h. After the reaction of the raw materials, they were dried by spin drying and purified by column to obtain 25 g of the product. 1 H NMR (400MHz, CDCl3) δ8.88(d,J=8.4Hz,1H),6.99(s,1H),6.72(d,J=12.0Hz,1H),3.98(s,3H),1.54(s,9H).

[0115] Synthesis of compound 3: Compound 2 (20 g, 69.9 mmol), N,N,N-trimethylethylenediamine (10.68 g, 104.8 mmol) and DIPEA (18.16 g, 139.8 mmol) were dissolved in N,N-dimethylacetamide and heated to 90°C for 16 h. After the reaction was completed, water and ethyl acetate were added to the reaction system for extraction, and the organic phases were combined and dried to obtain 30 g of the product.

[0116] Synthesis of compound 4: Compound 3 (30 g, 81.3 mmol), iron powder (31.8 g, 56.9 mmol) and ammonium chloride (30.4 g, 56.9 mmol) were dissolved in ethanol / water and heated to 85°C for 3 h. After the reaction was completed, the mixture was filtered and most of the solvent was removed by spinning. Ammonia water was then added to the reaction system, the pH was adjusted to 9-10, and the mixture was extracted with dichloromethane three times. After spinning, 24 g of the product was obtained. 1 H NMR (400MHz, CDCl3) δ7.54(s,1H),6.97(s,1H),6.62(s,1H),3.79(s,3H),3.54(m,4H) ,3.09(t,J=6.4Hz,2H),2.68(d,J=6.4Hz,2H),2.65(s,3H),2.50(s,6H),1.50(s,9H).

[0117] Synthesis of INT 4: Compound 4 (5 g, 14.7 mmol) and triethylamine (4.48 g, 44.3 mmol) were dissolved in dichloromethane and cooled to 0°C under nitrogen protection. Then, a dichloromethane solution of acryloyl chloride (1.48 g, 16.2 mmol) was slowly added dropwise and kept at 0°C for 2 h. After the reaction was completed, water and dichloromethane were added to the reaction system, extracted, dried by spin drying, and purified by column to obtain 3.3 g of product. 1H NMR (400MHz, CDCl3) δ10.05(s,1H),9.12(s,1H),6.91(s,1H),6.71(s,1H),6.43(dd,J=17.2,1.6Hz,1H),6.27(dd,J=16.8,10.0 Hz,1H),5.66(dd,J=10.0,1.6Hz,1H),3.82(s,3H),2.89-2.82(m,2H),2.66(s,3H),2.30-2.26(m,2H),2.25(s,6H),1.52(s,9H).

[0118] Intermediate 5

[0119] Synthesis route:

[0120]

[0121] 23g of raw material INT4 was dissolved in 50ml of THF. It was cooled to -5℃ in an ice-salt bath and added dropwise to 100ml of concentrated hydrochloric acid at a temperature of T<10℃. After stirring for 2 hours, the spot reaction was completed. After treatment, it was passed through a column to obtain 5.2g of product. 1 H NMR(CDCl3)δ10.10(s,1H),7.97(s,1H),6.68(s,1H),6.41-6.21(m,2H),5. 65(m,1H),3.81(s,3H),3.76(s,2H),2.82(m,2H),2.65(s,3H),2.20(s,6H).

[0122] Intermediate 6

[0123] The synthetic route is as follows:

[0124]

[0125] Synthesis of compound 2: Compound 1 (50 g, 0.26 mol), trifluoroethanol (29.61 g, 0.26 mol), and dry THF 700 mL were added to a 2000 mL three-necked flask, and NaH (12 g, 0.286 mol) was added in batches at 0°C under nitrogen protection, and then stirred at room temperature overnight. After TLC detection, saturated ammonium chloride aqueous solution was added, extracted with ethyl acetate three times, washed with saturated brine, dried, spin-dried, and passed through a column to obtain 53 g of the product. 1 HNMR: (CDCl3, 400MHz) δ8.36 (d, J = 8.0 Hz, 1H), 7.19 (d, J = 8.4 Hz, 1H), 4.94 ~ 4.88 (m, 2H).

[0126] Synthesis of compound 3: In a 2000mL three-necked flask, add compound 2 (40g, 0.156mol), NH4Cl (42g, 0.78mol), 600mL ethanol and 200mL water, heat to 80°C under nitrogen protection, add iron powder (44g, 0.78mol) in batches, stir and react for 2h after addition, TLC shows that the reaction is complete. Cool to room temperature, filter, spin-dry the filtrate, add 1000mL ethyl acetate, wash with water, dry, and spin-dry to obtain 30g of the product. 1 HNMR: (CDCl3, 400MHz) δ6.93 (d, J = 7.6 Hz, 1H), 6.83 (d, J = 8.0 Hz, 1H), 4.78 ~ 4.74 (m, 2H), 3.82 (s, 2H).

[0127] Synthesis of compound 4: In a 1000mL three-necked flask, add compound 3 (30g, 0.132mol), DIPEA (33mL, 0.192mol), and 600mL of dichloromethane. Under nitrogen protection, cool to 0°C. Add acetyl chloride (12g, 0.169mol) dropwise. After the addition is complete, stir and react at 0°C for 3h, and monitor with a plate. After the reaction is complete, add 100mL of water and 400mL of 1N hydrochloric acid aqueous solution, extract with dichloromethane three times, combine the organic phases, wash with water, dry, and spin dry to obtain 24g of the product. 1 HNMR: (CDCl3, 400MHz) δ8.67 (d, J = 8.0 Hz, 1H), 7.43 (s, 1H), 7.03 (d, J = 8.4 Hz, 1H), 4.85 ~ 4.79 (m, 2H), 2.24 (s, 3H).

[0128] Synthesis of compound 5: In a 500mL three-necked flask, add trifluoroacetic anhydride (200mL) and compound 4 (20g, 75mmol), then cool to -10℃, slowly add fuming nitric acid (3.5mL), keep the temperature at -5℃, stir for 1h under this temperature condition, and track the reaction with a plate. Pour the reaction solution into crushed ice, extract with ethyl acetate three times, dry, spin dry, and pass through a column to obtain 16g of the product. 1 HNMR: (DMSO-d6, 400MHz) δ9.95 (s, 1H), 9.18 (s, 1H), 5.17~5.15 (m, 2H), 2.18 (s, 3H).

[0129] Synthesis of compound 6: In a 250 mL single-mouth bottle, add compound 5 (10.4 g, 33.2 mmol), N,N,N-trimethylethylenediamine (5.08 g, 49.8 mmol), and 100 mL of acetonitrile. Then, heat to 80 ° C under nitrogen protection and stir overnight. Track the reaction on the spot plate. After the reaction is completed, spin dry the reaction solution, add methyl tert-butyl ether to pulp, filter, and dry to obtain 8.6 g of the product. 1 HNMR: (DMSO-d6, 400MHz) δ9.50 (s, 1H), 8.60 (s, 1H), 5.17~5.15 (m, 2H), 4.05 ( t, d=7.6Hz, 2H), 3.36 (t, d=7.4Hz, 2H), 2.83 (s, 3H), 2.79 (s, 6H), 2.08 (s, 3H).

[0130] Synthesis of compound 7: In a 250 mL single-mouth bottle, add THF 160 mL, compound 6 (8 g, 20.8 mmol), DMAP (0.72 g, 2.08 mmol), Boc2O (44.8 g, 208 mmol), then heat to 80 ° C under nitrogen protection, stir and react for 2 h, and track the reaction with a plate. The reaction is complete. After treatment, the product is passed through a column to obtain 8 g of the product with a yield of 83%.

[0131] Synthesis of compound 8: In a 250mL three-necked flask, add 150mL of anhydrous methanol and compound 7 (8g, 16.6mmol), cool to 0°C under nitrogen protection, add sodium methoxide (1.18g, 21.9mmol) in batches, and then stir the reaction under this condition for 1h. Track the reaction on the spot plate. After the reaction is completed, add water, extract with ethyl acetate three times, combine the organic phases, wash with water, dry, and spin dry to obtain product 7.2 with a yield of 90%.

[0132] Synthesis of compound 9: In a 250mL three-necked flask, add compound 8 (6.1g, 14mmol), NH4Cl (3.7g, 53.4mmol), 90mL ethanol and 30mL water, heat to 80℃ under nitrogen protection, add iron powder (3.9g, 70mmol) in batches, stir and react for 2h under this condition. Track the reaction with a spot plate, and the reaction is complete. Cool to room temperature, filter, spin dry the filtrate, add ethyl acetate and saline, treat, and spin dry to obtain 3.6g of the product with a yield of 64%.

[0133] Synthesis of INT6: In a 250mL three-necked flask, add 100mL of dichloromethane, compound 9 (3.5g, 8.6mmol), triethylamine (1.74g, 17.2mmol), under nitrogen protection, cool to -5℃, add acryloyl chloride (0.851g, 9.4mmol) in batches, stir and react for 0.5h, and track with a dot plate. After the reaction is completed, add saturated sodium bicarbonate aqueous solution, extract with dichloromethane three times, wash with water, dry, spin dry and pass through a column to obtain 1.9g of product. 1 HNMR: (CDCl3, 400MHz) δ 10.13 (s, 1H), 9.38 (s, 1H), 6.60 (s, 1H), 6.43 (d, J = 5.6Hz, 1H) 5.17~5. 15 (m, 2H), 4.05 (t, d = 7.6Hz, 2H), 3.36 (t, d = 7.4Hz, 2H), 2.83 (s, 3H), 2.79 (s, 6H), 2.08 (s, 3H).

[0134] Intermediate 7

[0135] Synthesis route:

[0136]

[0137] Compound 1 (20 g, 107.5 mmol), N,N,N-trimethylethylenediamine (12 g, 118.2 mmol) and potassium carbonate (30 g, 215 mmol) were added to acetonitrile, and then the temperature was raised to 80°C for 16 h. After the reaction was completed, the filter cake was washed with ethyl acetate three times, the filtrate was combined, dried, and spin-dried to obtain 37 g of the product. 1 H NMR (400MHz, CDCl3) δ7.25(s,1H),6.59(s,1H),3.89(s,3H),3.75(s,2H),3.18-3.09(m,2H),2.79(s,3H),2.50-2.43(m,2H),2.21(s,6H).

[0138] Intermediate 8

[0139] Synthesis route:

[0140]

[0141] Synthesis of compound 2: Compound 1 (13 g, 62.8 mmol) and aluminum chloride (9.9 g, 94.2 mmol) were dissolved in 200 mL of dry THF, heated to 80°C under nitrogen protection for 1 h, and INT-1 THF solution (12.5 g, 75.3 mmol) was slowly added dropwise under stirring, and the reaction was continued at 80°C for 3 h after the addition was completed, and the plate was tracked. After the reaction was completed, the mixture was treated and passed through a column to obtain 8.6 g of the product.1 H NMR (400MHz, CDCl3) δ8.83 (d, J = 0.8Hz, 1H), 8.19-8.13 (m, 1H), 7.98 (s, 1H), 7.40-7.28 (m, 3H), 3.89 (s, 3H), 3.86 (s, 3H).

[0142] Synthesis of INT 8: Compound 2 (8.6 g, 28.5 mmol) and intermediate 7 (9.2 g, 34.2 mmol) were dissolved in dioxane and water, p-toluenesulfonic acid monohydrate (8.14 g, 42.8 mmol) was added under stirring, and the temperature was raised to 80°C for reaction for 16 h. The reaction was completed by spot plate tracking, the reaction liquid was dried, 2N sodium hydroxide aqueous solution was added to adjust the base, and then extracted with ethyl acetate three times, dried, dried, and passed through a column to obtain 9 g of the product. 1 H NMR (400MHz, CDCl3) δ9.44(s,1H),8.90(s,1H),8.07(s,1H),7.78(s,1H),7.68(s,1H),7.41-7.35(m,1H),7.30(d,J=1.2Hz,1H),7. 23-7.18(m,2H),6.72(s,1H),4.00(s,3H),3.94(s,3H),3.71(s,3H),3.37(d,J=7.2Hz,2H),2.90(s,3H),2.70(s,2H),2.37(s,6H).

[0143] Intermediate 9

[0144] Synthesis route:

[0145]

[0146] Compound 1 (1 g, 3.07 mmol), AZD9291 intermediate (0.686 g, 3.69 mmol), and p-toluenesulfonic acid monohydrate (0.76 g, 3.99 mmol) were added to dry dioxane, and the temperature was raised to 80°C under nitrogen protection, and the reaction was carried out for 16 hours. The reaction was tracked by spot plate, and the reaction was completed, treated, and passed through a column to obtain 0.23 g of product. 1 H NMR (400MHz, CDCl3) δ9.74 (d, J = 8.4Hz, 1H), 8.88 (s, 1H), 8.02 (s, 1H), 7.89 (s, 1H), 7.38 (m, 2H), 7 .26(m,1H),7.11(t,J=7.6Hz,1H),6.79(d,J=12.0Hz,1H),4.05(s,3H),3.93(s,3H),2.33(s,3H).

[0147] Intermediate 10

[0148] Synthesis route:

[0149]

[0150] Synthesis of compound 2: INT8 (4.06 g, 7.62 mmol) and lithium hydroxide monohydrate (1.6 g, 38.1 mmol) were added to a mixed solvent of methanol, tetrahydrofuran and water, and the reaction was carried out at 40°C for 16 h. The reaction was monitored by TLC. After the reaction of the raw materials was completed, they were directly dried by spin-drying. Anhydrous methanol and concentrated hydrochloric acid were then added to adjust the mixture to neutrality. The solvent was then dried by spin-drying. Subsequently, 6.5 g of a crude product was obtained by dehydrating with toluene three times and the mixture was directly used for the next step.

[0151] Synthesis of INT 10: Compound 2 (6.5 g), DIPEA (5.8 g, 45 mmol) and tert-butyl carbazate (2.97 g, 22.5 mmol) were dissolved in dry DMF and reacted at room temperature for 15 min. PyBop (4.68 g, 9 mmol) was then added and reacted at room temperature for 16 h under nitrogen protection. After the reaction was completed, water and ethyl acetate were added to the reaction system for extraction. The organic phases were combined, dried, spin-dried, and column-filtered to obtain 1.9 g of the product. 1 H NMR(400MHz,DMSO-d6)δ10.32(s,1H),9.26(m,1H),9.11(s,1H),8.71(s,1H),8.4 0(s,1H),8.35(s,1H),8.30(s,1H),8.16(m,1H),7.48(d,J=8.2Hz,1H),7.22(ddd ,J=8.2,7.0,1.2Hz,1H),7.04(t,J=7.6Hz,1H),6.94(s,1H),3.96(s,3H),3.83(s ,3H),3.48(t,J=6.9Hz,2H),3.31(m,2H),2.86(s,3H),2.80(s,6H),1.49(s,9H).

[0152] 2. The following are specific examples of compounds used as kinase inhibitors:

[0153] Example 1

[0154] The structural formula of the compound used as a kinase inhibitor in this example is:

[0155]

[0156] Synthesis route:

[0157]

[0158] Synthesis of compound 2: In a 100mL single-necked bottle, add compound 1 (0.234g, 1mmol), AlCl3 (0.186g, 1.4mol), 1,2-dichloroethane 15mL, heat to 80℃ in an oil bath and stir for 1h, then add cyclopropylindole (0.16g, 1mmol), stir at 80℃ for 4h, track the reaction on a plate, after the reaction is complete, cool, pour into ice water, extract with ethyl acetate, extract 3 times, combine the organic phases, dry, and pass through a column to obtain 0.2g of the product.

[0159] Synthesis of Example 1: Compound 2 (50 mg, 0.141 mmol), INT 6 (65 mg, 0.141 mmol), p-toluenesulfonic acid monohydrate (45.5 mg, 0.24 mmol), NMP 1.5 mL and ethylene glycol monomethyl ether 3 mL were added to a 5 mL reactor, heated to 120°C, and reacted for 6 h. The reaction was complete with spot plate tracking, cooled to room temperature, 10 mL of ethyl acetate was added at room temperature, washed with sodium bicarbonate aqueous solution, washed once with saturated brine, and dried. After purification, 20 mg of the product was obtained with a yield of 51%. MS+1: 681.51.

[0160] Example 2

[0161] The structural formula of the compound used as a kinase inhibitor in this example is:

[0162]

[0163] Synthesis route:

[0164]

[0165] Synthesis of compound 2: In a 100mL single-necked bottle, add compound 1 (0.234g, 1mmol), AlCl3 (0.186g, 1.4mol), 1,2-dichloroethane 15ml, heat to 80℃ in an oil bath and stir for 1h, then add INT2 (0.138g, 1mmol), stir at 80℃ for 4h, track with a plate, after the reaction is complete, cool, pour into ice water, extract with ethyl acetate, extract 3 times, combine the organic phases, dry, and pass through a column to obtain 0.19g of product.

[0166] Synthesis of Example 2: Compound intermediate 2 (50 mg, 0.152 mmol), INT 6 (70.1 mg, 0.152 mmol), p-toluenesulfonic acid monohydrate (49.1 mg, 0.26 mmol), 1 mL of NMP and 2 mL of ethylene glycol monomethyl ether were added to a 5 mL reactor, heated to 120°C, reacted for 6 h, and the reaction was complete after tracking with a plate. The reaction was cooled to room temperature, 10 mL of ethyl acetate was added, and the mixture was washed once with sodium bicarbonate aqueous solution and saturated brine, dried, and purified to obtain 22 mg of the product. MS+1: 655.53.

[0167] Example 3

[0168] The structural formula of the compound used as a kinase inhibitor in this example is:

[0169]

[0170] Synthesis route:

[0171]

[0172] Synthesis of compound 2: Add compound 1 (5.53 g, 31 mmol), acetylhydrazine (2.76 g, 37 mmol) to a 250 ml single-mouth bottle, add 93 mL of 1N sodium hydroxide aqueous solution, react at 80°C for 4 h, and a large amount of yellow solid precipitates. Cool down, stir at low temperature of about 5°C for 30 min, filter, wash the filter cake with water once, and vacuum dry at 55°C overnight to obtain 2.75 g of product.

[0173] Synthesis of compound 3: Add compound 2 (2.75 g, 14.2 mmol), DIPEA (12.8 g, 0.1 mol), and 150 ml of toluene to a 250 ml single-mouth bottle. Add 20 ml of phosphorus oxychloride at room temperature, and white mist will be generated. Heat the mixture to 80 ° C in an oil bath, protect with nitrogen, and stir overnight. The next day, pour the reaction solution into crushed ice, add ethyl acetate for extraction, extract three times, combine the organic phases, dry, and pass through a column to obtain 1.1 g of the product. 1 H NMR (400MHz, CDCl3) δ9.18 (s, 1H), 2.70 (s, 3H).

[0174] Synthesis of compound 4: Add compound 3 (2.38 g, 10.3 mmol) and 120 mL of 1,2-dichloroethane to a 250 ml single-mouth bottle, add anhydrous aluminum chloride (2.318 g, 17.5 mmol), stir at room temperature for 30 min, then cool to 0 ° C, add 1.5 g of INT 2 dropwise, stir at low temperature for 30 min, then heat to 50 ° C, react for 2 hours, monitor with a plate, cool, pour into ice water, extract twice with dichloromethane, dry, spin dry, and pass through a column to obtain 1.24 g of the product.1 H NMR (400MHz, CDCl3) δ8.84(s,1H),8.05-8.00(m,1H),7.96(s,1H),7.42-7.26(m,3H),2.50(s,3H).

[0175] Synthesis of Example 3: INT 6 (50 mg, 0.11 mmol), compound 4 (35 mg, 0.11 mmol), p-toluenesulfonic acid (31 mg, 0.17 mmol), NMP 1 mL and ethylene glycol monomethyl ether 2 mL were added to a 5 mL reactor, heated to 120 ° C, reacted for 6 h, cooled to room temperature, added 10 mL of ethyl acetate, washed with sodium bicarbonate aqueous solution, washed once with saturated brine, dried, spin-dried, purified, and obtained 5 mg of the product. MS+1: 651.50.

[0176] Example 4

[0177] The structural formula of the compound used as a kinase inhibitor in this example is:

[0178]

[0179] Synthesis route:

[0180]

[0181] Synthesis of compound 2: In a 250 ml single-mouth bottle, add compound 3 (2.38 g, 10.3 mmol), 1,2-dichloroethane 120 mL, anhydrous aluminum chloride (2.33 g, 17.5 mmol), stir at room temperature for 30 min, then cool to 0 ° C, add 1.62 g INT3 dropwise, stir at low temperature for 30 min, then heat to 50 ° C, react for 2 hours, cool, pour into ice water, add dichloromethane to extract twice, dry, spin dry, pass through a column, and obtain 1.5 g of the product.

[0182] Synthesis of Example 4: INT 6 (50 mg, 0.11 mmol), compound 2 (39 mg, 0.11 mmol), p-toluenesulfonic acid monohydrate (35.5 mg, 0.187 mmol), NMP 1 mL and ethylene glycol monomethyl ether 2 mL were added to a 5 mL reactor, heated to 120 ° C, reacted for 6 h, cooled to room temperature, added 10 mL of ethyl acetate, washed with sodium bicarbonate aqueous solution, washed once with saturated brine, dried, purified, and obtained 5 mg of the product. MS+1: 677.50.

[0183] Example 5

[0184] The structural formula of the compound used as a kinase inhibitor in this example is:

[0185]

[0186] Synthesis route:

[0187]

[0188] Synthesis of Example 5: Add the compound of Example 1 (50 mg, 0.073 mmol), NaOH (5.3 mg, 0.13 mmol), and 2 mL of methanol into a 5 mL reactor, heat to 70°C, react for 6 h, cool to room temperature, add 10 mL of ethyl acetate, wash with sodium bicarbonate aqueous solution, wash once with saturated brine, dry, and purify to obtain 5 mg of the product. MS+1: 671.51.

[0189] Example 6 and Example 7

[0190] The structural formula of the compounds used as kinase inhibitors in Examples 6 and 7 is:

[0191] Embodiment 6: Embodiment 7:

[0192] Synthesis route:

[0193]

[0194] Synthesis of compound 2: Sodium hydride (0.55 g, 13.75 mmol, 60%) and toluene 20 mL were added to a 50 mL three-necked flask, and ethyl formate (1.1 g, 14.86 mmol) was slowly added dropwise at 0°C under nitrogen protection. After addition, the mixture was stirred at 0°C for 10 minutes, and a toluene (10 mL) solution of 2-indanone (1.5 g, 11.36 mmol) was added dropwise. After addition, the mixture was heated to room temperature and stirred overnight. The next day, the mixture was diluted with water, and the pH was adjusted to 4 with concentrated hydrochloric acid. The aqueous phase was extracted three times with ethyl acetate, and the organic phases were combined, washed with water, dried, and spin-dried to obtain 3.5 g of a crude product.

[0195] Synthesis of compound 3: 3.5 g of crude compound 2, hydrazine hydrate (1.8 g, 27.95 mmol), glacial acetic acid (1.61 g, 26.81 mmol), and 30 mL of ethanol were added to a 50 mL three-necked flask, and heated at 85 ° C for 3 h under nitrogen protection. Concentrate, dilute with water, extract with ethyl acetate three times, wash with water, dry, and pass through a column to obtain 1.35 g of the product.

[0196] Synthesis of Compound 4 and Compound 5: Compound 3 (156 mg, 1 mmol) and 5 mL of N,N-dimethylformamide were added to a 10 mL reactor, respectively, and sodium hydride was added at 0°C. After addition, the mixture was stirred for 0.5 h, and 2,4-dichloropyrimidine-5-carboxylic acid isopropyl ester (280 mg, 1.2 mmol) was added dropwise. After addition, the mixture was heated to room temperature and stirred overnight. The next day, water was added to quench the mixture, and the aqueous phase was extracted three times with ethyl acetate. The organic phases were combined, washed with water, dried, and passed through a column to obtain 85 mg of Compound 4 and Compound 5.

[0197] Synthesis of Example 6 and Example 7: Compound 4 (50 mg, 0.14 mmol), Compound 5 (50 mg, 0.14 mmol), INT 5 (82 mg, 0.28 mmol), p-toluenesulfonic acid monohydrate (26.8 mg, 0.14 mmol), DCE (5 mL), and n-pentanol (5 mL) were added to a 10 mL reactor, respectively, and the mixture was heated to 95° C. and stirred overnight under nitrogen protection. The next day, water was added to quench the mixture, and the aqueous phase was extracted three times with dichloromethane. The organic phases were combined, concentrated, column-filtered, and purified to obtain 5 mg of Example 6 and 9 mg of Example 7. Example 6: 1 HNMR(400MHZ,CDCl3)δ13.20(s,1H),9.78(s,1H),9.33(s,1H),9.11(S,1H),8.55(s,1H), 8.11(s,1H),7.63(d,J=4Hz,1H),7.46(d,J=2Hz,1H),7.31(dd,J=8Hz,1H),7.06-6.99(m,1 H), 6.71 (s, 1H), 6.62 (d, J = 8 Hz, 1H), 5.82 (d, J = 6 Hz, 1H), 5.29-5.25 (m, 1H), 3.89 (s, 3H), 3.79 (s, 2H), 3.28 (s, 2H), 3.17 (s, 2H), 2.83 (s, 6H), 2.65 (s, 3H), 1.30 (d, J = 2 Hz, 1H). Example 7: 1HNMR(400MHZ,CDCl3)δ12.98(s,1H),11.10(s,1H),9.85(s,1H),9.44-9.34(m,1H ),9.11(s,1H),7.64(s,1H),7.46(s,1H),6.99-6.96(m,1H),6.76(s,1H),6.59(d ,J=8Hz,1H),5.82(d,J=4Hz,1H),5.34-5.33(m,1H),4.58(s,2H),3.97(s,3H),3. 89-3.88(m,2H),3.31(s,2H),3.20(s,2H),2.86(s,7H),2.67(s,3H),1.42(S,6H).

[0198] Example 8

[0199] The structural formula of the compound used as a kinase inhibitor in this example is:

[0200]

[0201] Synthesis route:

[0202]

[0203] Synthesis of compound 2: Compound 1 (0.94 g, 4.3 mmol) and 20 mL of 1,2-dichloroethane were added to a 100 mL single-mouth bottle, and aluminum chloride (1.06 g, 8 mmol) was added under an ice bath, stirred for 5 minutes, and then INT1 (0.52 g, 4 mmol) was added, and then heated at 50°C for 1.5 h. After the reaction, water was added, and the mixture was extracted three times with dichloromethane, and the organic phases were combined, washed with water, dried, and passed through a column to obtain 0.6 g of the product. 1 HNMR (400MHZ, CDCl3) δ8.81 (s, 1H), 8.16 (t, J = 4Hz, 1H), 7.96 (s, 1H), 7.38-7.36 (m,1H),7.33-7.29(m,2H),4.35-4.30(m,2H),3.87(s,1H),1.24(t,J=8Hz,3H).

[0204] Synthesis of compound 3: Compound 2 (0.6 g, 1.904 mmol), INT 5 (0.50 g, 1.713 mmol), p-toluenesulfonic acid monohydrate (0.361 g, 1.904 mmol), 1,2-dichloroethane 5 mL and 1-pentanol 5 mL were added to a 50 mL single-mouth bottle and heated to 70 ° C for 36 h. After the reaction, the reaction solution was evaporated, dichloromethane was added to dissolve, washed with water, dried, and passed through a column to obtain 0.6 g of the product. 1HNMR(400MHZ,CDCl3)δ9.75(s,1H),8.90(s,1H),8.65(s,1H),7.89(s,1H),7.52(s,1H),7.32(d,J=4Hz,1H),7.20(t,J=8Hz,1H),7.12(t,J=8Hz, 1H),3.75(s,1H),6.46(d,J=8Hz,1H),5.70(d,J=8Hz,1H),3.93(s,1H), 3.87(s,1H),2.99(s,2H),2.70(s,3H),2.41(s,7H),0.93(t,J=4Hz,3H).

[0205] Synthesis of compound 4: Compound 3 (0.4 g, 0.70 mmol), sodium hydroxide (0.084 g, 2.1 mmol), 10 mL of water and 10 mL of tetrahydrofuran were added to a 100 mL single-mouth bottle and stirred at room temperature for 30 h. After the reaction was completed, the reaction solution was dried by spin-drying, and water was added to dissolve it. The insoluble matter was filtered out, and the pH of the aqueous phase was adjusted to about 5 with 1N dilute hydrochloric acid. The aqueous phase was dried by spin-drying to obtain 0.4 g of a crude product.

[0206] Synthesis of Example 8: Add compound 4 (0.2 g, 0.368 mmol), methanesulfonamide (0.106 g, 1.1 mmol), 2-chloro-1-methylpyridinium iodide (0.112 g, 0.44 mmol), triethylamine (0.112 g, 1.1 mmol), DMAP (2.24 mg, 0.002 mmol) and 5 mL of N,N-dimethylformamide into a 50 mL single-mouth bottle and stir at room temperature for 36 h. After the reaction is complete, add saturated salt water, extract with dichloromethane three times, wash with water, dry and purify to obtain 34 mg of product. MS+1: 621.48.

[0207] Example 9

[0208] The structural formula of the compound used as a kinase inhibitor in this example is:

[0209]

[0210] Synthesis route:

[0211]

[0212] Synthesis of Example 9: Compound 1 (0.2 g, 0.368 mmol), methanesulfonylmethylamine (0.12 g, 1.1 mmol), 2-chloro-1-methylpyridinium iodide (0.112 g, 0.44 mmol), triethylamine (0.112 g, 1.1 mmol), DMAP (2.24 mg, 0.002 mmol) and 5 mL of N,N-dimethylformamide were added to a 50 mL single-mouth bottle, and stirred at room temperature for 24 h. After the reaction was completed, saturated brine was added, and the mixture was extracted with dichloromethane three times, washed with water, dried, and purified to obtain 20 mg of the product. MS+1: 635.48.

[0213] Example 10

[0214] The structural formula of the compound used as a kinase inhibitor in this example is:

[0215]

[0216] Synthesis route:

[0217]

[0218] Synthesis of compound 2: Compound 1 (1.85 g, 8.4 mmol) and 40 mL of 1,2-dichloroethane were added to a 100 mL single-mouth bottle, and aluminum chloride (2.13 g, 16 mmol) was added under ice bath, stirred for 5 minutes, and then INT 2 (1.2 g, 9 mmol) was added, and then heated at 50°C for 1.5 h. After the reaction, ice water was added, and dichloromethane was extracted three times, washed with water, dried, and passed through a column to obtain 1.3 g of the product.

[0219] Synthesis of compound 3: Add compound 2 (100 mg, 0.32 mmol) and tetrahydrofuran (8 mL) to a 50 mL three-necked flask, cool to 0 ° C, add lithium aluminum tetrahydride (24 mg, 0.631 mmol) under nitrogen protection, and stir overnight. The next day, cool, add saturated ammonium chloride aqueous solution to quench, and extract with ethyl acetate three times. Dry, spin dry, and pass through a column to obtain 40 mg of the product. 1 HNMR: (CDCl3, 400MHz) δ 8.57~8.50 (m, 1H), 8.03 (s, 1H), 7.37~7.33 (m, 3H), 4.77 (d, J = 2.4Hz, 2H).

[0220] Synthesis of Example 10: In a 10 mL single-mouth bottle, compound 3 (32 mg, 0.12 mmol), INT6 (64.5 mg, 0.14 mmol), Pd2 dba3 (14.8 mg, 0.016 mmol), X-Phos (18.4 mg, 0.032 mmol), potassium phosphate (56 mg, 0.3 mmol), and dioxane (3.2 mL) were added in sequence. Under nitrogen protection, the mixture was heated to 100 ° C and stirred for 12 h. After the reaction was completed, water and ethyl acetate were added, extracted three times, the organic phases were combined, dried, spin-dried, and purified to obtain 10 mg of the product. 1 HNMR: (CD3OD, 400MHz) δ 8.49 (s, 1H), 8.34 (s, 1H), 8.26 ~ 8.23 ​​(m, 2H), 7.50 (d, J = 8.0Hz, 1H), 7.27 ~ 7.23 (m, 1H), 7.10 ~ 7.06 (m, 1H), 6. 50~6.35(m,2H),5.88~5.85(m,1H),4.97~4.85(m,2H),4.69(s,2H),3.84~3.81(m,2H),3.36~3.31(m,2H),3.91(s,6H),2.84(s,3H).

[0221] Embodiment 11

[0222] The structural formula of the compound used as a kinase inhibitor in this example is:

[0223]

[0224] Synthesis route:

[0225]

[0226] Synthesis of compound 2: In a 250mL three-necked flask, add NaH (5.7g, 142.4mmol) and toluene (50mL), cool the internal temperature to about 5°C with an ice bath, add ethyl formate (10.54g, 142.4mmol), cool the reaction solution to about 2°C after the addition, drop 50mL of toluene solution of compound 1 (9.4g, 71.2mmol), control the internal temperature between 0 and 4°C during the period, drip in about 30 minutes, remove the ice bath after the dripping, and naturally warm to room temperature, stir and react overnight. The next day, a large amount of solid precipitated, add 70mL of water, adjust pH to 1-2 with concentrated hydrochloric acid, extract twice with ethyl acetate, dry, and concentrate to obtain 13.64g of crude product.

[0227] Synthesis of compound 3: Take 13.64 g of the crude product from the previous step, add 100 mL of ethanol, 80% hydrazine hydrate (11.83 g, 175.2 mmol) and glacial acetic acid (10.1 g, 168 mmol), reflux the mixture for 3 h, evaporate the solvent under reduced pressure, add 80 mL of ethyl acetate and 60 mL of water to the residue, extract with ethyl acetate twice, combine the organic phases, dry, concentrate, and beat to obtain 9.1 g of the product. 1 HNMR: (CDCl3, 400MHz) δ7.80~7.78 (d, J=7.6Hz, 1H), 7.51~7.48 (m, 2H), 7.38~7.34 (m, 1H), 7.31~7.27 (m, 1H), 3.67 (s, 2H).

[0228] Synthesis of compound 4: Add compound 3 (200 mg, 1.28 mmol) and 6 mL DMF to a 100 mL single-mouth bottle, cool to about 5 ° C in an ice bath under nitrogen protection, add NaH (61.5 mg, 1.54 mmol), a small amount of bubbles escape, and stir the reaction solution in an ice bath for 20 minutes after addition, then add 2,4-dichloropyrimidine-5-carboxylic acid isopropyl ester (330 mg, 1.41 mmol) in DMF 2 mL, the reaction solution turns brown-red after addition, warm to room temperature and stir overnight. The next day, add water and ethyl acetate, separate the liquids, extract the aqueous phase with ethyl acetate twice, combine the organic phases, dry, concentrate, and pass through a column to obtain 138 mg of the product. 1 HNMR: (CDCl3, 400MHz) δ9.06 (s, 1H), 8.35 (s, 1H), 7.94 (d, J = 7.6Hz, 1H), 7.41 (d, J = 7 .2Hz, 1H), 7.36~7.28(m,2H), 5.29~5.23(m,1H), 3.68(s,2H), 1.38(d,J=6.4Hz,6H).

[0229] Synthesis of Example 11: In a 25 mL single-necked bottle, compound 4 (138 g, 0.39 mmol) and INT 5 (113.8 mg, 0.39 mmol) were added, followed by p-toluenesulfonic acid monohydrate (74.1 mg, 0.39 mmol), n-pentanol (5.5 mL) and 1,2-dichloroethane (5.5 mL). The mixture was heated in a 90 ° C oil bath with stirring overnight. The next day, water and dichloromethane were added, the liquids were separated, and the aqueous phase was extracted twice with dichloromethane. The organic phases were combined, dried, concentrated, and passed through a column to obtain 108 mg of a relatively pure crude product, which was then purified to obtain 43 mg of a pure product. 1HNMR: (CDCl3, 400MHz) δ11.14(s,1H),9.68(s,1H),9.20~9.0(m,3H),7.93(s,1 H),7.49(s,1H),7.37~7.34(m,2H),6.98~6.91(m,1H),6.72(s,1H),6.55~6.51 (m,1H),5.83~5.80(m,1H),5.37~5.32(m,1H),3.91(s,3H),3.73(s,2H),3.32~ 3.30(m,2H),3.27~3.26(m,2H),2.89(s,1H),2.67(s,3H),1.44(d,J=6Hz,6H).

[0230] Example 12

[0231] The structural formula of the compound used as a kinase inhibitor in this example is:

[0232]

[0233] Synthesis route:

[0234]

[0235] Synthesis of compound 2: In a 100 mL single-necked bottle, compound 1 (200 mg, 1.28 mmol) and 6 mL of DMF were added. The mixture was cooled in an ice bath under nitrogen protection to an internal temperature of about 5°C. NaH (61.5 mg, 1.54 mmol) was added, and a small amount of bubbles escaped. After the addition, the reaction solution was placed in an ice bath and stirred for 20 minutes. Then 2 mL of a DMF solution of 2,4-dichloropyrimidine-5-carboxylic acid isopropyl ester (330 mg, 1.41 mmol) was added thereto with a syringe. After the addition, the reaction solution turned brown-red. The ice bath was not removed and the mixture was allowed to naturally rise to room temperature and stirred overnight. Water and ethyl acetate were added to the reaction solution, and the mixture was separated after stirring. The aqueous phase was extracted twice with ethyl acetate. The organic phases were combined, dried, concentrated, and passed through a column to obtain 108 mg of compound 2. 1 HNMR: (CDCl3, 400MHz) δ8.59(s,1H),8.34(s,1H),7.71~7.69(m,1H),7.49~7.47( m,1H),7.39~7.35(m,2H),5.40~5.33(m,1H),3.74(s,2H),1.40(d,J=6.8Hz,6H).

[0236] Synthesis of Example 12: In a 25 mL single-necked bottle, compound 2 (108 g, 0.31 mmol) and INT 5 (89.1 mg, 0.31 mmol) were added, followed by p-toluenesulfonic acid monohydrate (57.9 mg, 0.31 mmol), 4.3 mL of n-pentanol and 4.3 mL of 1,2-dichloroethane. The mixture was heated in an oil bath at 90°C with stirring to react overnight. Dichloromethane was added to the residue, stirred and separated, the aqueous phase was extracted twice with dichloromethane, the organic phases were combined, dried, concentrated, and passed through a column to obtain 25 mg of a relatively pure crude product, which was then purified to obtain 9 mg of a pure product. 1 HNMR: (CDCl3, 400MHz) δ12.43(s,1H),9.48(s,1H),9.11~9.02(m,3H),8.48(s,1H),7 .72(d,J=4.8Hz,1H),7.51(d,J=4.8Hz,1H),7.38~7.36(m,2H),6.97~6.91(m,1H),6.7 2(s,1H),6.54~6.50(m,1H),5.80(d,J=9.6Hz,1H),5.30~5.29(m,1H),3.89(s,3H),3. 78(s,2H),3.30(s,2H),3.20(s,2H),2.85(s,6H),2.65(s,3H),1.34(d,J=6.4Hz,6H).

[0237] Embodiment 13

[0238] The structural formula of the compound used as a kinase inhibitor in this example is:

[0239]

[0240] Synthesis route:

[0241]

[0242] Synthesis of compound 2: In a 100 mL single-mouth bottle, compound 1 (200 mg, 1.28 mmol) and 6 mL of DMF were added. Under nitrogen protection, the mixture was cooled to an internal temperature of about 5°C with stirring in an ice bath. NaH (61.5 mg, 1.54 mmol) was added, and a small amount of bubbles escaped. After the addition, the reaction solution was placed in an ice bath and stirred for reaction for 20 minutes. Then 2 mL of DMF solution of 2,4-dichloropyrimidine (210 mg, 1.41 mmol) was added thereto with a syringe. After the addition, the reaction solution turned brown-red. The ice bath was not removed and the mixture was allowed to naturally rise to room temperature and stirred overnight. Water and ethyl acetate were added to the reaction solution, the liquids were separated, and the ethyl acetate was extracted twice. The organic phases were combined, dried, concentrated, and passed through a column to obtain 83 mg of the product.

[0243] Synthesis of Example 13: Compound 2 (50 mg, 0.19 mmol) and INT 5 (54.4 mg, 0.19 mmol) were added to a reaction flask, followed by p-toluenesulfonic acid monohydrate (35.5 mg, 0.19 mmol), 2 mL of n-pentanol and 2 mL of 1,2-dichloroethane. The mixture was heated and stirred in a 90°C oil bath for overnight reaction. The next day, water and dichloromethane were added, the liquids were separated, and dichloromethane was extracted twice more. The organic phases were combined, dried, concentrated, and passed through a column to obtain 79 mg of the product. 1 HNMR: (CDCl3, 400MHz) δ10.09(s,1H),9.79(s,1H),9.37(s,1H),8.43(d,J=5.2Hz,1H),7.89(d,J=7.2Hz,1H),7.84(s,1H),7.52(d,J=7.6Hz 1H),7.41~7.32(m,3H),6.79(s,1H),6.56~6.51(m,1H),6.44~6.38(m,1H),5.76~5.73(m,1H),3.89(s,3 H),3.81(s,2H),2.92~2.89(m,2H),2.70(s,3H),2.36~2.33(m,2H),2.29(s,6H),2.03(d,J=3.6Hz,1H).

[0244] Embodiment 14

[0245] The structural formula of the compound used as a kinase inhibitor in this example is:

[0246]

[0247] Synthesis route:

[0248]

[0249] Synthesis of compound 2: Compound 1 (1 g, 6.40 mmol) was dissolved in 25 mL DMF, then NIS (1.73 g, 7.68 mmol) was added, and the reaction was carried out at 80°C overnight, and the plate was tracked. The next day, the reaction was completed, the reaction solution was cooled to room temperature, and water and ethyl acetate were added for extraction. The organic phase was washed with saturated brine, dried, concentrated, and passed through a column to obtain 1.17 g of the product. 1 HNMR: (DMSO-d6, 400MHz) δ13.50 (s, 1H), 7.63~7.53 (m, 2H), 7.37~7.27 (m, 2H), 3.54 (s, 2H).

[0250] Synthesis of compound 3: Compound 2 (600 mg, 2.13 mmol) was dissolved in anhydrous THF, the reaction temperature was lowered to 0-5°C, NaH (94 mg, 2.34 mmol) was added, and the reaction was carried out at 0-5°C for 30 minutes, and then iodomethane (5.54 mmol) was added dropwise at 0-5°C, and the temperature was slowly raised to room temperature and the reaction was carried out overnight. The next day, the reaction was completed, water was added to quench the reaction, ethyl acetate was extracted, and the organic phase was washed with saturated brine, dried, concentrated, and passed through a column to obtain 279 mg of the product. 1 HNMR: (DMSO-d6, 400MHz) δ7.56 (d, J = 7.6 Hz, 1H), 7.52~7.37 (m, 1H), 7.34~7.33 (m, 1H), 7.31~7.26 (m, 1H), 4.08 (s, 3H), 3.47 (s, 2H).

[0251] Synthesis of compound 4: Compound 3 (109 mg, 0.37 mmol) was dissolved in 4 mL of dry 1,4-dioxane, and hexabutyl ditin (0.43 g, 0.74 mmol) and tetrakis(triphenylphosphine) palladium (20.8 mg, 0.018 mmol) were added, and the mixture was reacted overnight at 100°C. The next day, 2 mL of 1N cesium fluoride aqueous solution was added, and the mixture was stirred at room temperature for 5 min, filtered, and the filtrate was extracted with ethyl acetate. The organic phase was washed with saturated brine, dried, concentrated, and passed through a column to obtain 49 mg of the product. 1 HNMR: (CDCl3, 400MHz) δ7.54~7.48(m,2H),7.35~7.29(m,1H),7.25~7.21(m,1H),4.17(s,3H),3.53(s, 2H),1.67~1.53(m,10H),1.40~1.36(m,7H),1.34~1.16(m,6H),1.14~1.13(m,5H),1.11~0.93(m,11H).

[0252] Synthesis of compound 5: Compound 4 (50 mg, 0.11 mmol) was dissolved in 2 mL of anhydrous 1,4-dioxane, and isopropyl 2,4-dichloropyrimidine-5-carboxylate (35 mg, 0.15 mmol) and tris(dibenzylideneacetone)dipalladium (41 mg, 0.045 mmol) were added. The mixture was reacted at 80 °C for 3.5 h. After the reaction, water and ethyl acetate were added for extraction. The organic phase was washed with saturated brine, dried, concentrated, and passed through a column to obtain 25 mg of the product. 1 HNMR: (CDCl3, 400MHz) δ 8.63 (s, 1H), 7.59 ~ 7.56 (m, 2H), 7.39 ~ 7.30 (m, 2H), 5.38 ~ 5.29 (m, 1H), 4.17 (s, 3H), 3.89 (s, 2H), 1.39 (d, J = 6.4Hz, 6H).

[0253] Synthesis of Example 14: Compound 5 (25 mg, 0.068 mol) was dissolved in 1 mL of 1,2-dichloroethane and 1 mL of n-pentanol, INT 5 (20 mg, 0.068 mmol) and p-toluenesulfonic acid monohydrate (13 mg, 0.068 mmol) were added, and the mixture was reacted at 90°C overnight. After the reaction, the reaction solution was concentrated, washed with saturated sodium bicarbonate aqueous solution, extracted with dichloromethane, and the organic phase was washed with saturated brine, dried, concentrated, and passed through a column to obtain 21 mg of the product. 1 HNMR: (CDCl3, 400MHz) δ8.64 (s, 1H), 8.42 (s, 1H), 7.71 (d, J = 7.6Hz, 1H), 7.56 (d, J = 7. 6Hz,1H),7.40(t,J=7.2Hz,1H),7.30(t,J=8.4Hz,1H),6.97(s,1H),6.49~6.47(m,2H), 5.84(dd,J=3.6,7.6Hz,1H),5.20~5.14(m,1H),4.17(s,3H),4.01(s,3H),3.73(s,2H), 3.51~3.48(m,2H),3.28~3.25(m,2H),2.86(s,6H),2.72(s,3H),1.28(d,J=6.4Hz,6H).

[0254] Embodiment 15

[0255] The structural formula of the compound used as a kinase inhibitor in this example is:

[0256]

[0257] Synthesis route:

[0258]

[0259] Synthesis of compound 2: Compound 1 (1 g, 6.40 mmol) was dissolved in 25 mL DMF, then NIS (1.73 g, 7.68 mmol) was added, and the reaction was carried out at 80°C overnight, and the plate was tracked. The next day, the reaction was completed, the reaction solution was cooled to room temperature, and water and ethyl acetate were added for extraction. The organic phase was washed with saturated brine, dried, concentrated, and passed through a column to obtain 1.17 g of the product. 1 HNMR: (DMSO-d6, 400MHz) δ13.50 (s, 1H), 7.63~7.53 (m, 2H), 7.37~7.27 (m, 2H), 3.54 (s, 2H).

[0260] Synthesis of compound 3: Compound 2 (3.18 g, 11.3 mmol) was dissolved in anhydrous 50 mL THF, the reaction temperature was lowered to 0-5°C, NaH (0.5 g, 12.4 mmol) was added, and the reaction was carried out at 0-5°C for 30 min, and then iodomethane (4.2 g, 29.3 mmol) was added dropwise at 0-5°C, and the temperature was slowly raised to room temperature and the reaction was carried out overnight. The next day, water was added to quench the reaction, and the mixture was extracted with ethyl acetate. The organic phase was washed with saturated brine, dried, concentrated, and passed through a column to obtain 195 mg of the product. 1 HNMR: (DMSO-d6, 400MHz) δ7.60(d,J=7.2Hz,1H),7.54(d,J=7.2Hz,1H),7.35(t,J=7.2Hz,1H),7.31~7.27(m,1H),3.93(s,3H),3.55(s,2H).

[0261] Synthesis of compound 4: Compound 3 (156 mg, 0.53 mmol) was dissolved in 5.3 mL of anhydrous 1,4-dioxane, hexabutyl ditin (0.61 g, 1.05 mmol) and tetrakis(triphenylphosphine) palladium (30 mg, 0.026 mmol) were added, and the mixture was reacted overnight at 100°C. The next day, water and ethyl acetate were added for extraction, and the organic phase was washed with saturated brine, dried, concentrated, and passed through a column to obtain 128 mg of the product. 1 HNMR: (CDCl3, 400MHz) δ7.75 (d, J = 7.6Hz, 1H), 7.47 (d, J = 7.2Hz, 1H), 7.35~7.31 (m, 1H), 7.25~7. 21(m,1H),4.01(s,3H),3.61(s,2H),1.68~1.52(m,25H),1.41~1.18(m,49H),0.94~0.88(m,32H).

[0262] Synthesis of compound 5: Compound 4 (122 mg, 0.26 mmol) was dissolved in 5 mL of anhydrous 1,4-dioxane, and 2,4-dichloropyrimidine-5-carboxylic acid isopropyl ester (87 mg, 0.37 mmol) and tris(dibenzylideneacetone)dipalladium (48.5 mg, 0.053 mmol) were added. The mixture was reacted at 80 °C for 3.5 h. After the reaction, water and ethyl acetate were added for extraction. The organic phase was washed with saturated brine, dried, concentrated, and passed through a column to obtain 29 mg of the product. 1HNMR: (CDCl3, 400MHz) δ9.08 (s, 1H), 7.79 (d, J = 7.6Hz, 1H), 7.45 (d, J = 7.6Hz, 1H), 7.39~7.35 ( m,1H),7.30~7.28(m,1H),5.19~5.10(m,1H),4.11(s,3H),3.54(s,2H),1.16(d,J=6.4Hz,6H).

[0263] Synthesis of Example 15: Compound 5 (30 mg, 0.08 mol) was dissolved in 1.2 mL of 1,2-dichloroethane and 1.2 mL of n-pentanol, INT 5 (23.3 mg, 0.08 mmol) and p-toluenesulfonic acid monohydrate (13 mg, 0.068 mmol) were added, and the mixture was reacted at 90°C overnight. After the reaction, the reaction solution was concentrated, washed with saturated sodium bicarbonate aqueous solution, extracted with dichloromethane, and the organic phase was washed with saturated brine, dried, concentrated, and passed through a column to obtain 22 mg of the product. 1 HNMR: (CDCl3, 400MHz) δ9.01 (s, 1H), 8.22 (s, 1H), 7.70 (d, J = 7.6Hz, 1H), 7.49 (d, J = 7.2Hz, 1H ),7.36(t,J=7.6Hz,1H),7.29(t,J=6.8Hz,1H),6.95(s,1H),6.51~6.37(m,2H),5.80(d,J=9. 6Hz,1H),5.06~4.99(m,1H),3.97(s,3H),3.92(s,3H),3.65~3.63(m,1H),3.56(s,2H),3.49~ 3.46(m,2H),3.41(s,1H),3.31~3.21(m,2H),2.83(s,6H),2.70(s,3H),1.10(d,J=6.4Hz,6H).

[0264] Example 16

[0265] The structural formula of the compound used as a kinase inhibitor in this example is:

[0266]

[0267] Synthesis route:

[0268]

[0269] Synthesis of compound 2: Compound 1 (1.85 g, 8.4 mmol) and DCE (40 mL) were added to a 100 mL single-mouth bottle, and aluminum chloride (2.13 g, 16 mmol) was added under an ice bath, stirred for 5 minutes, and then INT2 (1.2 g, 9 mmol) was added, and then heated at 50°C for 1.5 h. After the reaction, water was added, and then extracted three times with dichloromethane, the organic phases were combined, washed once with saturated brine, dried, and passed through a column to obtain 1.3 g of the product.

[0270] Synthesis of Example 16: INT 6 (50 mg, 0.11 mmol), compound 2 (36 mg, 0.11 mmol), p-toluenesulfonic acid monohydrate (31 mg, 0.17 mmol), 1 mL of NMP and 2 mL of ethylene glycol monomethyl ether were added to a 5 mL reactor, heated to 120°C, reacted for 6 h, cooled to room temperature, added with 10 mL of ethyl acetate, washed with sodium bicarbonate aqueous solution, washed once with saturated brine, dried, and purified to obtain 20 mg of the product. MS+1: 641.52

[0271] Embodiment 17

[0272] The structural formula of the compound used as a kinase inhibitor in this example is:

[0273]

[0274] Synthesis route:

[0275]

[0276] Synthesis of Example 17: Add the compound of Example 16 (50 mg, 0.078 mmol), NaOH (36 mg, 0.9 mmol), and 2 mL of ethanol into a 5 mL reactor, heat to 70°C, react for 6 h, cool to room temperature, and when the raw materials react completely, add 10 mL of ethyl acetate, wash with sodium bicarbonate aqueous solution, wash once with saturated brine, dry, and purify to obtain 15 mg of the product. MS+1: 613.48.

[0277] Embodiment 18

[0278] The structural formula of the compound used as a kinase inhibitor in this example is:

[0279]

[0280] Synthesis route:

[0281]

[0282] Synthesis of compound 2: Compound 1 (2 g, 10.1 mmol) was dissolved in dichloromethane, cooled to 0°C under nitrogen protection, and a dichloromethane solution of Boc2O (2.42 g, 11.1 mmol) was slowly added dropwise, followed by DMAP (0.25 g, 2.05 mmol) and the temperature was slowly raised to room temperature for 16 h. After the reaction of the raw materials, the reaction was concentrated and column chromatography was performed to obtain 1.6 g of compound 2. 1 H NMR (400MHz, CDCl3) δ4.76 (s, 1H), 3.66 (d, J = 11.2Hz, 2H), 3.37 (td, J = 11.6, 4.0Hz,2H),2.28(s,1H),1.65(dt,J=7.6,5.2Hz,2H),1.43(d,J=8.8Hz,18H).

[0283] Synthesis of compound 3: Add lithium aluminum tetrahydride (1.75 g, 46 mmol) to dry tetrahydrofuran, cool to 0°C under nitrogen protection, slowly drop a tetrahydrofuran solution of compound 2 (1.6 g, 5.36 mmol), then heat to 70°C and react for 16 h. After the reaction of the raw materials, cool to 0°C, slowly drop 2 mL of water and 2 mL of 20% sodium hydroxide aqueous solution, and filter to obtain 1.48 g of compound 3.

[0284] Synthesis of compound 4: INT 9 (250 mg, 0.526 mmol), compound 3 (100 mg, 0.793 mmol) and DIPEA (203 mg, 1.57 mmol) were added to N,N-dimethylacetamide and reacted at 100°C for 16 h. After the reaction of the raw materials, water was added to the reaction system, and ethyl acetate was extracted three times. The organic phases were combined, washed with brine, dried, concentrated, and passed through a column to obtain 280 mg of the product.

[0285] Synthesis of compound 5: Compound 4 (280 mg, 0.481 mmol) and palladium carbon (56 mg, 20%) were added to methanol and reacted at room temperature for 2 h under a hydrogen atmosphere. After the reaction of the raw materials, diatomaceous earth was added for filtration, and the filter cake was washed three times with methanol. The filtrate was combined and dried to obtain 190 mg of compound 5.

[0286] Synthesis of Example 18: Compound 5 (190 mg, 0.345 mmol) and triethylamine (104 mg, 1.03 mmol) were dissolved in dichloromethane, cooled to 0°C under nitrogen protection, and then a dichloromethane solution of acryloyl chloride (41 mg, 0.45 mmol) was added dropwise, and the reaction was maintained at 0°C for 2 hours. After the reaction of the raw materials, saturated sodium bicarbonate aqueous solution was added, and the mixture was extracted with dichloromethane three times. The organic phases were combined, washed with brine, dried, concentrated, and passed through a column to obtain 30 mg of the product. 1H NMR (400MHz, CDCl3) δ10.54(s,1H),9.66(s,1H),8.89(m,2H),7.97(s,1H),7.3 2(d,J=8.0Hz,1H),7.16(t,J=8.0Hz,1H),6.98(m,2H),6.84(s,1H),6.44(dd,J= 16.8,2.0Hz,1H),6.36-6.24(m,1H),5.69(dd,J=10.0,2.0Hz,1H),3.99(s,3H) ,3.90(s,3H),3.05(m,1H),2.65(m,7H),2.32(s,3H),2.20(s,3H),1.08(s,2H).

[0287] Embodiment 19

[0288] The structural formula of the compound used as a kinase inhibitor in this example is:

[0289]

[0290] Synthesis route:

[0291]

[0292] Synthesis of compound 2: Compound 1 (5 g, 28.9 mmol) and AlCl3 (5.76 g, 43.3 mmol) were dissolved in 50 mL of dry 1,2-dichloroethane, heated to 80°C under nitrogen protection and reacted for 1 h, then methyl indole dichloroethane solution (4.53 g, 34.6 mmol) was slowly added dropwise under stirring, and the reaction was continued at 80°C for 3 h after the addition was completed. After the reaction was completed, the temperature was lowered, ice water was slowly poured in, and dichloromethane was extracted three times, the organic phases were combined, dried, and passed through a column to obtain 2.6 g of the product.

[0293] Synthesis of compound 3: Compound 2 (1.5 g, 5.6 mmol) and INT-7 (1.8 g, 6.71 mmol) were dissolved in dioxane and water, p-toluenesulfonic acid monohydrate (1.59 g, 8.37 mmol) was added, and the temperature was raised to 80°C for reaction for 16 h. After the reaction of the raw materials, the reaction liquid was dried, 2N sodium hydroxide aqueous solution was added to adjust the base, and then extracted with ethyl acetate three times, the organic phases were combined, dried, concentrated, and passed through a column to obtain 2.5 g of the product.

[0294] Synthesis of compound 4: Compound 3 (0.5 g, 1 mmol) was dissolved in a mixed solvent of ethanol and water, iron powder (0.448 g, 8 mmol) and ammonium chloride (0.43 g, 8 mmol) were added under stirring, and the temperature was raised to 80°C for reaction for 2 h. After the reaction of the raw materials, the ethanol was removed by rotation, ammonia water was added to adjust the base, and then extracted with ethyl acetate three times, the organic phases were combined, dried, and concentrated to obtain 0.45 g of crude product.

[0295] Synthesis of compound 5: Compound 4 (0.45 g), hydroxylamine hydrochloride (0.4 g, 5.74 mmol) and anhydrous potassium acetate (1.125 g, 11.4 mmol) were added to a mixed solvent of ethanol and dioxane, and refluxed at 80°C for 16 h. After the raw materials were reacted, most of the solvent was removed by vortexing, and then water and ethyl acetate were added and extracted three times. The organic phases were combined, dried, concentrated, and passed through a column to obtain 0.37 g of the product.

[0296] Synthesis of compound 6: Compound 5 (0.37 g, 0.734 mmol) and 2,2-dimethoxypropane (0.61 g, 5.87 mmol) were dissolved in a mixed solvent of 1,2-dichloroethane and acetic acid, and refluxed at 80°C for 2 h. After the reaction of the raw materials, most of the solvent was removed by vortexing. Saturated sodium bicarbonate solution was then added to adjust the pH to 8, and the mixture was extracted with dichloromethane three times. The organic phases were combined, dried, concentrated, and passed through a column to obtain 0.17 g of the product.

[0297] Synthesis of Example 19: Compound 6 (0.17 g, 0.312 mmol) and triethylamine (47 mg, 0.468 mmol) were dissolved in dry dichloromethane, cooled to 0°C, and then a dichloromethane solution of acryloyl chloride (31 mg, 0.343 mmol) was added dropwise, and the temperature was kept at 0°C for 2 hours. After the reaction of the raw materials, water and dichloromethane were added, and the mixture was extracted three times. The organic phases were combined, dried, concentrated, and passed through a column to obtain 60 mg of the product. 1 H NMR (400MHz, CDCl3): δ10.15(s,1H),10.13(s,1H),9.92(s,1H),9.16(s,1H),8.62 8.60(m,1H),8.54(s,1H),7.36-7.34(m,1H),7.24-7.23(m,3H),6.82(m,1H),6.50- 6.37(m,2H),5.71(dd,J=22.64,2.6Hz,1H),3.97(s,3H),3.93(s,3H),2.92(t,J=5. 4,5.8Hz,2H),2.71(s,3H),2.32(t,J=5.72,5.64Hz,2H),2.28(s,6H),1.63(s,6H).

[0298] Embodiment 20

[0299] The structural formula of the compound used as a kinase inhibitor in this example is:

[0300]

[0301] Synthesis route:

[0302]

[0303] Synthesis of compound 2: INT 8 (5 g, 9.38 mmol) was dissolved in ethanol and water, and iron powder (4.2 g, 75.1 mmol) and ammonium chloride (4.1 g, 75.1 mmol) were added under stirring. After the addition was completed, the temperature was raised to 80°C for reaction for 2 h. After the reaction of the raw materials, most of the ethanol in the reaction solution was removed by vortexing, and then ammonia water was added to adjust the base, and then extracted with ethyl acetate three times, the organic phases were combined, dried, and concentrated to obtain 5 g of crude product.

[0304] Synthesis of compound 3: Compound 2 (5 g) and lithium hydroxide (2.08 g, 49.7 mmol) were added to a mixed solvent of methanol, tetrahydrofuran and water and reacted at room temperature for 16 h. After the reaction of the raw materials, most of the solvent was removed by vortexing, and then 4.6 g of crude product was obtained after dehydrating with toluene three times.

[0305] Synthesis of compound 4: The crude product of compound 3 (2 g), DIPEA (1.58 g, 12.2 mmol) and hydroxylamine hydrochloride (0.84 g, 12.2 mmol) were dissolved in dry DMF, reacted at room temperature for 15 minutes, PyBop (2.5 g, 4.91 mmol) was added, and the reaction was carried out at room temperature for 16 hours under nitrogen protection and monitored by TLC. After the raw materials reacted, water and ethyl acetate were added to the reaction system for extraction, and the organic phases were combined, dried, concentrated, and passed through a column to obtain 0.6 g of the product.

[0306] Synthesis of compound 5: Compound 4 (0.6 g, 1.18 mmol) and 2,2-dimethoxypropane (0.99 g, 9.51 mmol) were dissolved in a mixed solvent of 1,2-dichloroethane and acetic acid, and refluxed at 80°C for 2 h. After the reaction of the raw materials, most of the solvent was removed by vortexing, and then a saturated sodium bicarbonate solution was added to adjust the pH to 8, followed by extraction with dichloromethane, extraction three times, and the organic phases were combined, dried, the solvent was vortexed, and passed through a column to obtain 0.13 g of the product.

[0307] Synthesis of Example 20: Compound 5 (0.13 g, 0.238 mmol) and triethylamine (36 mg, 0.357 mmol) were dissolved in dry dichloromethane, cooled to 0°C, and then a dichloromethane solution of acryloyl chloride (0.0238 g, 0.262 mmol) was added dropwise, and the temperature was kept at 0°C for 2 hours. After the reaction of the raw materials, water was added, and the dichloromethane was extracted three times. The organic phases were combined, dried, concentrated, and passed through a column to obtain 14 mg of the product. 1 H NMR (400MHz, CDCl3): δ8.95(s,1H),8.54(s,1H),8.20(s,1H),2.92(d,J=8.12Hz,2H),7. 86(s,1H),7.31-7.22(m,2H),7.10(t,J=7.64,7.32Hz,1H),6.63(s,1H),6.59-6.53(m,1 H),6.30(d,J=16.52Hz,1H),5.71(d,J=10.24Hz,1H),3.86(s,3H),3.80(s,3H),3.31(t, J=5.4,5.8Hz,2H),3.16(t,J=5.72,5.64Hz,2H),2.73(s,6H),2.60(s,3H),1.48(s,6H).

[0308] Embodiment 21

[0309] The structural formula of the compound used as a kinase inhibitor in this example is:

[0310]

[0311] Synthesis route:

[0312]

[0313] Synthesis of compound 2: Add 90 ml of dioxane hydrochloride to a 250 ml single-mouth bottle under nitrogen protection. Dissolve INT 10 (1.52 g, 2.40 mmol) in 50 ml of dry THF and add dropwise to the reaction bottle. Then take 10 ml of dry THF and add dropwise to the reaction bottle. Stir at 40 °C for 4 h, cool to 0 °C, filter, wash the filter cake with dry THF, and vacuum dry to obtain 1.324 g of product.

[0314] Synthesis of compound 3: Compound 2 (0.843 g, 1.48 mmol) was taken, 16 mL of triethyl orthoformate was added, and the mixture was refluxed at 160°C for 2 hours. The solvent was evaporated under reduced pressure, the temperature was lowered, a mixture of methanol and dichloromethane was added to dissolve, and the mixture was filtered through a column to obtain 0.154 g of pure product. 1H NMR (400MHz, DMSO-d6) δ9.27(s,1H),8.99(s,1H),8.62(s,1H),8.26(s,1H),7.86(s,1H),7.48(d,J=8.3Hz,1H),7.44(s,1H),7.21(d ,J=15.2Hz,1H),7.01(s,1H),6.84(s,1H),3.91(s,3H),3.78(s,3H),3.33(s,13H),2.87(s,3H),2.50(p,J=1.9Hz,14H),2.19(s,5H).

[0315] Synthesis of compound 4: Compound 3 (154 mg, 0.284 mmol), zinc powder (110 mg, 1.69 mmol) and ammonium chloride (149 mg, 2.78 mmol) were added to 3 mL of acetone and 0.3 mL of water. After addition, the temperature was raised to 26 °C and reacted for 2 h. A saturated aqueous solution of sodium bicarbonate, dichloromethane and a small amount of methanol were added, extracted twice, dried, and spin-dried to obtain 0.235 g of crude product, which was directly used in the next step.

[0316] Synthesis of Example 21: In a 100 mL single-mouth bottle, add crude compound 4 (0.235 g), 10 mL of dichloromethane, triethylamine (85 mg, 0.84 mmol), cool to 0°C, add acryloyl chloride (33 mg, 0.37 mmol) dropwise, and keep the temperature at 0°C for 3 hours. After the reaction of the raw materials, add saturated sodium bicarbonate aqueous solution, extract twice with dichloromethane, dry, concentrate, and pass through a column to obtain 15 mg of the product. 1 HNMR(400MHz, CDCl3)δ10.17(s,1H),9.78(s,1H),8.92(s,1H),8.85(m,1H),8 .16(s,1H),7.97(s,1H),7.31(d,J=8.2Hz,1H),7.15(t,J=6.2Hz,1H),6.94(d ,J=7.2Hz,2H),6.80(m,2H),6.53-6.35(m,2H),5.81-5.64(m,1H),3.95(s,3H ),3.89(s,4H),2.90(t,J=5.5Hz,2H),2.70(s,3H),2.32(s,2H),2.28(s,6H).

[0317] Examples 22 and 23

[0318] Referring to Example 18, Examples 22 and 23 were synthesized, as shown in Table 1 below:

[0319] Table 1 Compounds of Examples 22 and 23

[0320] Embodiment 24

[0321] The structural formula of the compound used as a kinase inhibitor in this example is:

[0322]

[0323] Synthesis route:

[0324]

[0325] Synthesis of compound 2: Add compound 1 (24 g, 133 mmol), acetylhydrazine (12.7 g, 172 mmol) and 400 mL of 1N sodium hydroxide aqueous solution to a 1000 mL single-mouth bottle, react at 80°C for 4 h, and a large amount of yellow solid precipitates. Cool down, add 33 mL of concentrated hydrochloric acid, stir at about 0°C for 30 minutes, filter, wash the filter cake with water once, and vacuum dry at 55°C overnight to obtain 18.8 g of yellow solid product.

[0326] Synthesis of compound 3: Add compound 2 (18.8 g, 97 mmol) to a 1000 mL single-mouth bottle, add 450 mL of toluene, phosphorus oxychloride (89.3 g, 583 mmol), and DIPEA (50.1 g, 389 mmol) at room temperature, and white mist will be generated. Heat to 80 ° C, protect with nitrogen, and stir overnight. The next day, spin off most of the solvent, pour the reaction solution into crushed ice, extract with ethyl acetate 3 times, combine the organic phases, dry, concentrate, and pass through a column to obtain 12.08 g of the product.

[0327] Synthesis of compound 4: Add compound 3 (2.38 g, 10.3 mmol) to a 250 mL single-mouth bottle, dissolve it in 120 mL 1,2-dichloroethane, add anhydrous aluminum chloride (2.33 g, 17.5 mmol), and stir at room temperature for 30 minutes. Cool to 0 ° C, add INT2 (1.52 g, 11.33 mmol) dropwise, stir at low temperature for 30 minutes, then heat to 50 ° C and react for 2 hours. Cool, pour into ice water, extract with dichloromethane twice, dry, spin dry, and pass through a column to obtain 1.24 g of the product. 1 H NMR (400MHz, CDCl3) δ8.84(s,1H),8.05-8.00(m,1H),7.96(s,1H),7.42-7.26(m,3H),2.50(s,3H).

[0328] Synthesis of Example 24: Compound 4 (0.397 g, 1.22 mmol), p-toluenesulfonic acid monohydrate (0.3 g, 1.58 mol), INT4 (0.526 g, 1.34 mmol), 20 mL of NMP and 40 mL of ethylene glycol monomethyl ether were added to a 100 mL single-mouth bottle. Stirred overnight at 120°C under nitrogen protection. The next day, 0.2 mL of 1N sodium hydroxide was added, and the mixture was extracted with ethyl acetate three times, dried, concentrated, and filtered to obtain 40 mg of the product. 1 H NMR (400MHz, CDCl3) δ10.22(s,1H),9.78(s,1H),8.89(m,2H),7.95(s,1H),7. 31(d,J=8.2Hz,1H),7.15(m,1H),6.97(t,J=7.8Hz,2H),6.80(s,1H),6.46(dd ,J=16.9,2.1Hz,1H),6.36(dd,J=17.0,9.9Hz,1H),5.71(dd,J=9.8,2.1Hz,1H ),3.88(s,3H),2.88(t,J=5.6Hz,2H),2.70(s,3H),2.26(s,8H),2.19(s,3H).

[0329] Embodiment 25

[0330] The structural formula of the compound used as a kinase inhibitor in this example is:

[0331]

[0332] Synthesis route:

[0333]

[0334] Synthesis of compound 2: 120 mL of dioxane hydrochloride was added to a 250 mL single-mouth bottle under nitrogen protection. INT 10 (2.08 g) was dissolved in 55 mL of dry THF and added dropwise to the reaction bottle, stirred at 40°C for 4 hours, cooled to 0°C, filtered, the filter cake was washed with THF, and vacuum dried to obtain 3.3 g of the product.

[0335] Synthesis of compound 3: Compound 2 (0.871 g, 1.53 mmol) and triethylamine (0.463 g, 4.59 mmol) were dissolved in dichloromethane, stirred for 5 minutes, cooled to 0°C in an ice bath, acetic anhydride (0.172 g, 1.683 mmol) was added dropwise, stirred at low temperature for 30 minutes, and then stirred overnight at 25°C. The next day, the raw material disappeared, sodium bicarbonate aqueous solution was added, and dichloromethane was extracted twice. The organic phases were combined, dried, and passed through a column to obtain 0.73 g of the product.

[0336] Synthesis of compound 4: Compound 3 (0.133 g) was taken, 0.4 g of Lawesson's reagent was added, and then 20 mL of THF was added, and the reaction was refluxed at 80°C for 2 hours until the raw material disappeared. The mixture was cooled, treated, and passed through a column to obtain 0.13 g of the product.

[0337] Synthesis of compound 5: Compound 4 (1.4 g, 2.44 mmol), zinc powder (0.955 g, 14.7 mmol) and ammonium chloride (1.31 g, 24.5 mmol) were added and the temperature was raised to 26°C for 2 h. When the raw material disappeared, a saturated aqueous solution of sodium bicarbonate was added, and the mixture was extracted twice with dichloromethane, dried, and concentrated to obtain 0.6 g of crude product, which was directly used in the next step.

[0338] Synthesis of Example 25: Compound 5 (0.6 g) and triethylamine (0.33 g, 3.26 mmol) were dissolved in 50 mL of dichloromethane, cooled to 0°C, acryloyl chloride (130 mg, 1.44 mmol) was added dropwise, and the temperature was kept at 0°C for 3 h until the raw materials were completely reacted. Saturated sodium bicarbonate aqueous solution was added, and dichloromethane was extracted twice, dried, concentrated, passed through a column, and purified to obtain 200 mg of the product. 1 H NMR(400MHz, CDCl3)δ9.77(s,1H),9.57(m,1H),8.90(s,1H),8.56(m,1H),7.8 9(s,1H),7.30(d,J=8.2Hz,1H),7.14(t,J=7.6Hz,1H),6.95(t,J=7.5Hz,2H),6 .71(s,1H),6.50(dd,J=16.8,2.0Hz,1H),5.76(ddd,J=10.0,7.9,1.9Hz,2H), 3.90(s,3H),3.88(s,3H),3.16(m,2H),2.86(m,2H),2.69(s,4H),2.61(s,9H).

[0339] Embodiment 26

[0340] The structural formula of the compound used as a kinase inhibitor in this example is:

[0341]

[0342] Synthesis route:

[0343]

[0344] Synthesis of compound 2: In a 100 mL single-mouth bottle, compound 1 (0.624 g, 2.71 mmol) was dissolved in 40 mL of 1,2-dichloroethane, aluminum chloride (0.613 g, 4.61 mmol) was added, stirred at room temperature for 30 minutes, cooled in an ice-salt bath, and a dichloroethane solution of indole (0.349 g, 2.98 mmol) was added dropwise. Stirred at low temperature for 30 minutes, heated to 50 ° C and stirred for 2 h, cooled, poured into ice water, extracted with ethyl acetate 3 times, combined the organic phases, dried, and passed through a column to obtain 0.245 g of a solid product.

[0345] Synthesis of Example 26: In a 100 mL single-mouth bottle, compound 2 (0.245 g, 0.79 mmol), p-toluenesulfonic acid (0.195 g, 1.03 mol), INT 4 (0.34 g, 0.87 mmol), NMP 10 mL, ethylene glycol monomethyl ether 20 mL were added, nitrogen was protected, and stirred at 120°C overnight. The next day, sodium hydroxide aqueous solution was added, and ethyl acetate was extracted three times. The ethyl ester phases were combined, concentrated, dried, and passed through a column to obtain 20 mg of the product. 1 H NMR (400MHz, CDCl3) δ10.27(m,1H),9.69(s,1H),9.27(s,1H),8.85(s,1H),8.43(m,1H),7.93(s,1H),7.34(d,J=8.1Hz,1H),7.10(t,J=7.6Hz, 1H),6.99(m,2H),6.80(s,1H),6.54-6.27(m,2H),5.70(dd,J=9.9,1.9 Hz, 1H), 3.88 (s, 3H), 2.89 (t, J = 5.5Hz, 2H), 2.71 (s, 3H), 2.26 (m, 11H).

[0346] Embodiment 27

[0347] The structural formula of the compound used as a kinase inhibitor in this example is:

[0348]

[0349] Synthesis route:

[0350]

[0351] Synthesis of compound 2: 90 mL of dioxane hydrochloride was added to a 250 mL single-mouth bottle under nitrogen protection. INT 10 (1.52 g) was dissolved in 50 mL of dry THF and added dropwise to the reaction bottle. Then 10 mL of THF was added dropwise to the reaction bottle. Stirred at 40°C for 4 h, cooled to 0°C, filtered, the filter cake was washed with THF, and vacuum dried to obtain 1.324 g of the product.

[0352] Synthesis of compound 3: Compound 2 (1.324 g) was taken, 17 mL of triethyl orthoacetate was added, and the reaction was refluxed at 160°C for 2 hours until the raw material disappeared. The solvent was evaporated under reduced pressure, the temperature was lowered, a mixture of methanol and dichloromethane was added to dissolve, and the mixture was passed through a column to obtain 0.42 g of pure product. 1 H NMR (400MHz, DMSO-d6) δ9.01(s,1H),8.60(s,1H),8.35(s,1H),7.94(m,1H),7.53(s,1H),7.49(d,J=8.2Hz,1H),7.27-7.19(m,1H),7. 04(d,J=7.8Hz,1H),6.91(s,1H),3.95(s,3H),3.80(s,3H),3.48(t,J=7.0Hz,2H),3.03(m,2H),2.86(s,6H),2.56(s,3H),2.47(s,3H).

[0353] Synthesis of compound 4: Compound 3 (420 mg, 0.75 mmol), zinc powder (294 mg, 4.5 mmol) and ammonium chloride (403 mg, 7.5 mmol) were added and the temperature was raised to 26°C for 2 h. When the raw material disappeared, a saturated aqueous solution of sodium bicarbonate was added, and the mixture was extracted twice with dichloromethane, dried, and spin-dried to obtain 667 mg of a crude product, which was directly used in the next step.

[0354] Example 27 Synthesis: 100mL single-mouth bottle, add 0.177g of 2-fluoroacrylic acid, 10mL of dichloromethane. Cool to -5°C in an ice-salt bath under nitrogen protection, drop 0.25g of oxalyl chloride and 2 drops of dry DMF, and react at low temperature for 2 hours. Take another 250mL single-mouth bottle, take the crude product of compound 4 (667mg) and DIPEA (490mg, 3.8mmol) and dissolve them in 100mL of dichloromethane, cool to 0°C, then drop homemade 2-fluoroacryloyl chloride, keep 0°C for 3h, after the raw materials react, add saturated sodium bicarbonate aqueous solution, extract twice with dichloromethane, dry, concentrate, and pass through a column to obtain 120mg of product. 1H NMR(400MHz,Chloroform-d)δ10.48(s,1H),9.61(s,1H),8.89(s,1H),8.63(s,1 H),7.98(s,1H),7.32(dt,J=8.4,0.9Hz,1H),7.17(t,J=8.0Hz,1H),7.00(d,J=7 .4Hz,1H),6.82(s,1H),5.76(dd,J=46.5,3.0Hz,1H),5.21(dd,J=14.9,3.0Hz,1 H),3.95(s,3H),3.91(s,3H),2.97(t,J=6.3Hz,2H),2.68(s,3H),2.21(s,11H).

[0355] Embodiment 28

[0356] The structural formula of the compound used as a kinase inhibitor in this example is:

[0357]

[0358] Synthesis route:

[0359]

[0360] Synthesis of compound 3: Compound 1 (1 g, 3.49 mmol), compound 2 (0.528 g, 4.19 mmol) and DIPEA (1.35 g, 10.46 mmol) were added to N,N-dimethylacetamide and reacted at 80°C for 16 h. After the reaction of the raw materials, water was added and extracted with ethyl acetate three times. The organic phases were combined, washed with brine, dried, concentrated, and passed through a column to obtain 1.2 g of the product.

[0361] Synthesis of compound 4: Compound 3 (1.2 g, 3.06 mmol) and palladium carbon (240 mg, 20%) were added to methanol and reacted at room temperature for 2 h under a hydrogen atmosphere. After the reaction of the raw materials, diatomaceous earth was added for filtration, and the filter cake was washed three times with methanol. The filtrate was combined and concentrated to obtain 1.1 g of crude product.

[0362] Synthesis of compound 5: Compound 4 (1.1 g, 3.04 mmol) and triethylamine (0.92 g, 9.11 mmol) were dissolved in dichloromethane, cooled to 0°C under nitrogen protection, and then a dichloromethane solution of acryloyl chloride (0.329 g, 3.95 mmol) was added dropwise, and the reaction was maintained at 0°C for 2 h. After the reaction of the raw materials, saturated sodium bicarbonate aqueous solution was added, and the dichloromethane was extracted three times. The organic phases were combined, washed with brine, dried, concentrated, and passed through a column to obtain 0.84 g of the product. 1H NMR (400MHz, CDCl3) δ8.90(s,1H),8.66(s,1H),6.87(s,1H),6.65(s,1H),6.42(dd,J=16.8,1.6Hz,1H),6.30(dd,J=16.8,10.0Hz,1H ),5.69(dd,J=10.0,1.6Hz,1H),3.81(s,3H),3.00-2.86(m,4H),2.82(d,J=9.6Hz,2H),2.66-2.54(m,2H),2.44(s,3H),1.51(m,11H).

[0363] Synthesis of Example 28: Compound 5 (0.256 g, 0.615 mmol), Compound 6 (0.2 g, 0.615 mmol) and p-toluenesulfonic acid monohydrate (0.14 g, 0.737 mmol) were added to a mixed solvent of ethylene glycol methyl ether and N-methylpyrrolidone, and the mixture was heated to 120°C for 16 h under nitrogen protection. After the reaction was completed, water and ethyl acetate were added to the reaction system, and the aqueous phase was extracted three times. The organic phases were combined, dried by rotation, and purified to obtain 1.28 mg of the product. MS+1: 606.52.

[0364] Embodiment 29

[0365] The structural formula of the compound used as a kinase inhibitor in this example is:

[0366]

[0367] Synthesis route:

[0368]

[0369] Synthesis of compound 2: 30 mL of dioxane hydrochloride was added to a 100 mL single-mouth bottle under nitrogen protection. INT 10 (0.5 g) was dissolved in 15 mL of dry THF and added dropwise to the reaction bottle. Then 5 mL of THF was added dropwise to the reaction bottle. The mixture was stirred at 40 ° C for 4 h, cooled to 0 ° C, filtered, and the filter cake was washed with THF and dried under vacuum to obtain 0.44 g of the product.

[0370] Synthesis of compound 3: Compound 2 (0.44 g, 0.77 mmol) and triethylamine (0.252 g, 2.5 mmol) were dissolved in dichloromethane, stirred for 5 minutes, cooled to 0°C in an ice bath, and difluoroacetic anhydride (0.147 g, 0.85 mmol) was added dropwise, stirred at low temperature for 30 minutes, and then stirred overnight at 25°C. The next day, the raw material disappeared, and sodium bicarbonate aqueous solution was added, extracted twice with dichloromethane, and the organic phases were combined, dried, and passed through a column to obtain 0.3 g of the product. 1H NMR (400MHz, DMSO-d6) δ10.7(m,2H)8.71(s,1H),8.24(m,4H),7.47(d,J=8.2Hz,1H),7.21(t,J=7.8Hz,1H),7.0 1(s,1H),6.84(s,1H),6.50(t,J=52.9Hz,1H),3.90(s,3H),3.82(s,3H),2.90(m,5H),2.53(m,2H),2.19(s,6H).

[0371] Synthesis of compound 4: Compound 3 (0.3 g) was taken, 1.5 g of Lawesson's reagent was added, and then 70 mL of THF was added, and the mixture was refluxed at 80°C for 2 hours. When the raw material disappeared, the mixture was cooled, treated, and passed through a column to obtain 0.185 g of pure product.

[0372] Synthesis of compound 5: Compound 4 (185 mg, 0.304 mmol), zinc powder (120 mg, 1.84 mmol) and ammonium chloride (160 mg, 2.99 mmol) were added and the temperature was raised to 26°C for 2 h. When the raw material disappeared, a saturated aqueous solution of sodium bicarbonate was added directly, and the mixture was extracted twice with dichloromethane, dried, and concentrated to obtain 155.4 mg of crude product, which was directly used in the next step.

[0373] Synthesis of Example 29: Compound 5 (416.2 mg) and triethylamine (250 mg) were dissolved in 40 mL of dichloromethane, cooled to 0°C, and then acryloyl chloride (90 mg) was added dropwise, and the temperature was kept at 0°C for 3 h. After the reaction of the raw materials, saturated sodium bicarbonate aqueous solution was added, extracted with dichloromethane twice, dried, concentrated, and purified to obtain 66 mg of the product. 1 H NMR(400MHz, CDCl3)δ9.79(s,1H),9.51(s,1H),8.99(s,1H),8.71(m,1H),7.97( s,1H),7.31(d,J=8.2Hz,1H),7.17-7.12(m,1H),7.03(m,1H),6.92(m,2H),6.91( s,1H),6.70(s,1H),6.50(dd,J=16.9,2.0Hz,1H),5.74(d,J=10.2Hz,1H),3.93(s ,3H),3.88(s,3H),3.18(t,J=5.8Hz,2H),2.92(m,2H),2.68(s,3H),2.65(m,6H).

[0374] Embodiment 30

[0375] The structural formula of the compound used as a kinase inhibitor in this example is:

[0376]

[0377] Synthesis route:

[0378]

[0379] Synthesis of compound 2: Compound 1 (3 g, 14.15 mmol) was dissolved in dichloromethane, cooled to 0°C under nitrogen protection, and a dichloromethane solution of Boc2O (3.3 g, 15.14 mmol) was slowly added dropwise under stirring, followed by DMAP (0.34 g, 2.79 mmol), and the temperature was slowly raised to room temperature and the reaction was continued for 16 h. After the reaction of the raw materials was completed, the raw materials were concentrated and passed through a column to obtain 3.7 g of the product. 1 H NMR (400MHz, CDCl3) δ4.62 (s, 1H), 3.99 (d, J = 8.0Hz, 1H), 3.93 (s, 2H), 3.83 (s, 2H) ),2.61-2.51(m,2H),1.99(ddt,J=11.2,8.4,2.4Hz,2H),1.43(d,J=1.2Hz,18H).

[0380] Synthesis of compound 3: Add lithium aluminum tetrahydride (1.87 g, 49.2 mmol) to dry THF, cool to 0°C under nitrogen protection, slowly drop a tetrahydrofuran solution of compound 2 (2.56 g, 8.2 mmol), then heat to 70°C and react for 16 h. After the reaction of the raw materials, cool to 0°C, slowly drop 2 mL of water and 2 mL of 20% sodium hydroxide aqueous solution, then filter to obtain 1.72 g of compound 3.

[0381] Synthesis of compound 4: INT 9 (200 mg, 0.421 mmol), compound 3 (88 mg, 0.628 mmol) and DIPEA (162 mg, 1.26 mmol) were added to N,N-dimethylacetamide and reacted at 100°C for 16 h. After the reaction of the raw materials, water and ethyl acetate were added, the aqueous phase was extracted three times with ethyl acetate, the organic phases were combined, washed with brine, dried, concentrated, and passed through a column to obtain 180 mg of compound 4.

[0382] Synthesis of compound 5: Compound 4 (180 mg, 0.321 mmol) and palladium carbon (36 mg, 20%) were added to methanol and reacted at room temperature for 2 h under a hydrogen atmosphere. After the reaction of the raw materials, diatomaceous earth was added for filtration, and the filter cake was washed three times with methanol. The filtrate was combined and dried to obtain 130 mg of compound 5.

[0383] Synthesis of Example 30: Compound 5 (130 mg, 0.23 mmol) and triethylamine (70 mg, 0.69 mmol) were dissolved in dichloromethane, cooled to 0°C under nitrogen protection, and then a dichloromethane solution of acryloyl chloride (27 mg, 0.299 mmol) was added dropwise, and the mixture was kept at 0°C for 2 hours. After the reaction of the raw materials, saturated sodium bicarbonate aqueous solution was added, and the mixture was extracted with dichloromethane three times. The organic phases were combined, washed with brine, dried, concentrated, and passed through a column to obtain 15 mg of the product. 1 HNMR(400MHz, CDCl3)δ9.78(s,1H),8.90(s,1H),8.83(m,2H),7.95(s,1H),7.32(d,J=8.0H z,1H),7.17(t,J=7.6Hz,1H),6.97(m,2H),6.80(s,1H),6.45(dd,J=16.8,1.7Hz,1H),6.34 (dd,J=16.8,10.0Hz,1H),5.79(dd,J=10.0,1.6Hz,1H),3.97(s,3H),3.90(s,3H),3.25(d, J=1.6Hz,1H),3.13(s,2H),2.63(s,3H),2.58(s,2H),2.40(s,3H),2.20(s,3H),1.5(m,4H).

[0384] Embodiment 31

[0385] The structural formula of the compound used as a kinase inhibitor in this example is:

[0386]

[0387] Synthesis route:

[0388]

[0389] Synthesis of compound 2: In a 250 mL single-mouth bottle, add compound 1 (5.32 g, 29.56 mmol) and hydrazine isobutyrate (3.576 g, 35.1 mmol), add 90 mL of 1N sodium hydroxide aqueous solution, react at 85 ° C for 5 h, cool, add 8 mL of concentrated hydrochloric acid to adjust the pH, stir in an ice-water bath for 20 minutes, filter, and vacuum dry the filter cake at 55 ° C overnight to obtain 2.05 g of the product.

[0390] Synthesis of compound 3: Add compound 2 (0.94 g, 4.23 mmol), 20 mL of toluene, POCl3 (2.4 ml), and DIPEA (2.8 ml) to a 100 mL single-mouth bottle and react overnight at 80°C. Cool down, spin off most of the solvent, pour the mother liquor into ice water, extract twice with ethyl acetate, dry, spin dry, and pass through a column to obtain 0.395 g of the product.1 H NMR (400MHz, CDCl3) δ9.20 (s, 1H), 3.33 (p, J = 7.0Hz, 1H), 1.48 (d, J = 7.0Hz, 6H).

[0391] Synthesis of compound 4: In a 100 mL single-mouth bottle, compound 3 (0.4 g, 1.54 mmol) was dissolved in 40 mL 1,2-dichloroethane, and anhydrous aluminum chloride (0.35 g, 2.63 mmol) was added. Stir at room temperature for 30 minutes, then cooled to 0°C, INT 1 (0.224 g, 1.71 mmol) was added dropwise, and stirred at low temperature for 30 minutes, then heated to 50°C and reacted for 2 hours. Cooled, poured into ice water, extracted twice with dichloromethane, dried, concentrated, and passed through a column to obtain 130 mg of the product. 1 H NMR (400MHz, CDCl3) δ8.88(s,1H),7.89(d,J=8.1Hz,1H),7.83(s,1H),7.37(dt,J=8.2,1.1Hz,1H),7.30(ddd,J=8 .3,6.9,1.2Hz,1H),7.23(ddd,J=8.1,7.0,1.2Hz,1H),3.85(s,3H),3.11(p,J=7.0Hz,1H),1.20(d,J=7.0Hz,6H).

[0392] Synthesis of Example 31: Compound 4 (130 mg, 0.368 mmol), p-toluenesulfonic acid monohydrate (91 mg, 0.478 mmol) and INT 4 (159 mg, 0.406 mmol) were added to 16 mL of ethylene glycol monomethyl ether and 8 mL of NMP, and refluxed at 120°C overnight. The next day, sodium hydroxide aqueous solution was added, extracted with ethyl acetate three times, dried, concentrated, and passed through a column to obtain 25 mg of the product. 1 HNMR(400MHz, CDCl3)δ10.24(s,1H),9.80(s,1H),8.91(m,2H),7.94(s,1H),7.3 0(d,J=8.2Hz,1H),7.16-7.08(m,1H),6.94(m,2H),6.80(s,1H),6.48(dd,J=16. 9,2.0Hz,1H),6.36(t,J=13.6Hz,1H),5.72(dd,J=9.8,2.1Hz,1H),3.96(s,3H), 3.89(s,3H),2.87(q,J=8.7,7.3Hz,3H),2.71(s,3H),2.26(s,8H),1.25(s,6H).

[0393] Embodiment 32

[0394] The structural formula of the compound used as a kinase inhibitor in this example is:

[0395]

[0396] Synthesis route:

[0397]

[0398] Synthesis of compound 2: Compound 1 (3 g, 15.0 mmol) was dissolved in dichloromethane, cooled to 0°C under nitrogen protection, and then a dichloromethane solution of Boc2O (3.59 g, 16.5 mmol) was slowly added dropwise under stirring, followed by DMAP (0.37 g, 3.0 mmol) and the temperature was slowly raised to room temperature and the reaction was continued for 16 h. After the reaction of the raw materials was completed, they were concentrated and passed through a column to obtain 2.5 g of the product.

[0399] Synthesis of compound 3: Lithium aluminum tetrahydride (1.89 g, 49.98 mmol) was added to dry tetrahydrofuran, cooled to 0°C under nitrogen protection, and then slowly added a tetrahydrofuran solution of compound 2 (2.5 g, 8.33 mmol) under stirring, and then heated to 70°C for 16 hours. After the reaction of the raw materials, the temperature was lowered to 0°C, and 2 mL of water and 2 mL of 20% sodium hydroxide aqueous solution were slowly added, and then filtered to obtain 2.1 g of the product.

[0400] Synthesis of compound 4: INT9 (300 mg, 0.631 mmol), compound 3 (122 mg, 0.947 mmol) and DIPEA (245 mg, 1.89 mmol) were added to N,N-dimethylacetamide and reacted at 100°C for 16 h. After the reaction of the raw materials, water and ethyl acetate were added to the reaction system, the aqueous phase was extracted three times with ethyl acetate, the organic phases were combined, washed with brine, dried, concentrated, and passed through a column to obtain 370 mg of the product.

[0401] Synthesis of compound 5: Compound 4 (300 mg, 0.514 mmol) and palladium carbon (60 mg, 20%) were added to methanol and reacted at room temperature for 2 h under a hydrogen atmosphere. After the reaction of the raw materials, diatomaceous earth was added for filtration, and the filter cake was washed three times with methanol. The filtrate was combined and concentrated to obtain 310 mg of the product.

[0402] Synthesis of Example 32: Compound 6 (270 mg, 0.488 mmol) and triethylamine (147 mg, 1.46 mmol) were dissolved in dichloromethane, cooled to 0°C under nitrogen protection, and then a dichloromethane solution of acryloyl chloride (58 mg, 0.634 mmol) was added dropwise, and the reaction was maintained at 0°C for 2 hours. After the reaction of the raw materials, dichloromethane and saturated sodium bicarbonate aqueous solution were added, the aqueous phase was extracted three times with dichloromethane, the organic phases were combined, washed with brine, dried, the solvent was spin-dried, and passed through a column to obtain 15 mg of the product. 1 H NMR(400MHz, CDCl3)δ9.71(s,1H),8.89(s,1H),8.80(m,1H),8.65(s,1H),7.92(s,1H),7.34-7.30( m,1H),7.16(t,J=7.6Hz,1H),6.98(m,2H),6.76(s,1H),6.42(dd,J=16.8,1.6Hz,1H),6.31(dd,J=1 6.8,10.0Hz,1H),5.78(dd,J=10.0,1.6Hz,1H),3.96(s,3H),3.89(s,3H),3.09-2.99(m,2H),2.73( td,J=11.6,2.0Hz,2H),2.37(s,6H),2.26-2.17(m,4H),2.07(s,2H),1.66(dd,J=12.0,4.0Hz,2H).

[0403] Embodiment 33

[0404] The structural formula of the compound used as a kinase inhibitor in this example is:

[0405]

[0406] Synthesis route:

[0407]

[0408] Synthesis of compound 2: In a 250 mL single-mouth bottle, add compound 1 (18.8 g, 103.2 mmol) and hydrazine propionate (10.6 g, 123.8 mmol), add 310 mL of 1N sodium hydroxide aqueous solution, react at 85 ° C for 5 h, cool, add 8 ml of concentrated hydrochloric acid to adjust the pH, stir in an ice-water bath for 2 h, filter, and vacuum dry the filter cake at 55 ° C overnight to obtain 6.7 g of product. 1 H NMR (400MHz, DMSO-d6) δ11.58(m,2H),8.14(s,1H),2.87(q,J=7.6Hz,2H),1.27(t,J=7.5Hz,3H).

[0409] Synthesis of compound 3: In a 500 mL single-mouth bottle, compound 2 (6.7 g, 32.2 mmol), 160 mL of toluene, POCl3 (18 ml, 0.2 mol), and DIPEA (21 ml, 0.13 mol) were added in sequence and reacted at 80°C overnight. The temperature was lowered, most of the solvent was removed, poured into ice water, extracted twice with ethyl acetate, dried, concentrated, and filtered to obtain 1.907 g of the product. 1 H NMR (400MHz, CDCl3) δ9.18 (s, 1H), 3.02 (q, J = 7.6Hz, 2H), 1.46 (t, J = 7.6Hz, 3H).

[0410] Synthesis of compound 4: In a 250 mL single-mouth bottle, compound 3 (1.95 g, 8.0 mmol) was dissolved in 180 mL 1,2-dichloroethane, and anhydrous aluminum chloride (1.81 g, 13.61 mmol) was added. Stir at room temperature for 30 minutes, then cool to 0°C, and INT 1 (1.15 g, 8.78 mmol) was added dropwise. Stir at low temperature for 30 minutes, then heat to 50°C and react for 2 hours. Cool, pour into ice water, extract twice with dichloromethane, dry, concentrate, and pass through a column to obtain 0.8 g of the product. 1 H NMR (400MHz, CDCl3) δ8.85 (s, 1H), 7.94 (dt, J = 8.0, 1.0Hz, 1H), 7.90 (s, 1H), 7.42-7.17(m,3H),3.84(s,3H),2.81(q,J=7.6Hz,2H),1.19(t,J=7.6Hz,3H).

[0411] Synthesis of Example 33: Compound 4 (291 mg, 0.86 mmol), p-toluenesulfonic acid monohydrate (213 mg, 1.12 mmol) and INT 4 (376 mg, 0.96 mmol) were added to a mixed solvent of ethylene glycol monomethyl ether and NMP, and refluxed at 120°C overnight. The next day, sodium hydroxide aqueous solution and ethyl acetate were added, extracted three times, dried, concentrated, and filtered to obtain 40 mg of the product. 1H NMR(400MHz, CDCl3)δ9.83(s,1H),9.75(m,1H),8.88(s,1H),8.75(m,1H),7. 91(s,1H),7.38-7.20(m,1H),7.18-7.06(m,1H),6.95(t,J=7.3Hz,3H),6.71( s,1H),6.46(dd,J=16.8,2.0Hz,1H),5.73(dd,J=9.9,2.1Hz,1H),3.92(s,3H ),3.87(s,3H),3.05(m,2H),2.69(m,5H),2.50(m,8H),0.81(d,J=8.0Hz,3H).

[0412] Embodiment 34

[0413] The structural formula of the compound used as a kinase inhibitor in this example is:

[0414]

[0415] Synthesis route:

[0416]

[0417] Synthesis of Example 34: 2-Fluoroacrylic acid (200 mg, 2.22 mmol) was dissolved in dichloromethane, and a drop of DMF was added as a catalyst. The mixture was cooled to 0°C under nitrogen protection, and then oxalyl chloride (198 mg, 1.55 mmol) was slowly added dropwise. After the addition was complete, the mixture was slowly heated to room temperature and the reaction was continued for 2 h. After TLC monitoring, the reaction of the raw materials was completed, the reaction was stopped and the mixture was set aside. Compound 1 (150 mg, 0.272 mmol) and DIPEA (105 mg, 0.816 mmol) were dissolved in dichloromethane, and the mixture was cooled to 0°C under nitrogen protection, and then the dichloromethane solution of 2-fluoroacryloyl chloride (39 mg, 0.353 mmol) was added dropwise. The mixture was kept at 0°C for 2 h. After the reaction of the raw materials was completed, dichloromethane and saturated sodium bicarbonate aqueous solution were added, and the mixture was extracted with dichloromethane three times. The organic phases were combined, washed with brine, dried, concentrated, and passed through a column to obtain 20 mg of the product. 1H NMR(400MHz, CDCl3)δ10.67(s,1H),9.55(s,1H),8.89(s,1H),8.72(m,1H),7.98(s,1H),δ7 .32(dt,J=8.3,0.9Hz,1H),7.17(t,J=8.0Hz,1H),7.00(m,2H),6.84(s,1H),5.71(dd,J=46. 4,2.8Hz,1H),5.18(dd,J=14.8,2.8Hz,1H),3.97(s,3H),3.91(s,3H),2.83(m,2H),2.67(s, 3H), 2.63 (t, J = 6.4Hz, 1H), 2.55 (m, 2H), 2.20 (d, J = 2.0Hz, 6H), 1.64 (dd, J = 7.2, 2.8Hz, 2H).

[0418] Embodiment 35

[0419] The structural formula of the compound used as a kinase inhibitor in this example is:

[0420]

[0421] Synthesis route:

[0422]

[0423] Synthesis of compound 2: 40 mL of dioxane hydrochloride was added to a 100 mL single-mouth bottle under nitrogen protection. INT 10 (0.9 g) was dissolved in 20 mL of dry THF and added dropwise to the reaction bottle. Then 5 mL of THF was added dropwise to the reaction bottle. The mixture was stirred at 40 ° C for 4 h, then cooled to 0 ° C, filtered, and the filter cake was washed with THF and dried under vacuum to obtain 0.67 g of the product.

[0424] Synthesis of compound 3: Compound 2 (0.458 g, 0.81 mmol) and triethylamine (0.243 g, 2.41 mmol) were dissolved in 30 mL of dichloromethane, stirred for 5 minutes, cooled to 0°C in an ice-water bath, and trifluoroacetic anhydride (0.204 g, 0.97 mmol) was added dropwise, stirred at low temperature for 30 minutes, and then stirred overnight at 25°C. The next day, the raw material disappeared, saturated sodium bicarbonate aqueous solution was added, and then a small amount of methanol was added, and dichloromethane was extracted 3 times, the organic phases were combined, dried, and passed through a column to obtain 0.3 g of the product.

[0425] Synthesis of compound 4: Compound 3 (0.3 g) was taken, 1.5 g of Lawesson's reagent was added, and then 70 mL of THF was added, and the mixture was refluxed at 80°C for 48 h. The mixture was cooled, treated, and passed through a column to obtain 0.66 g of a crude product.

[0426] Synthesis of compound 5: Compound 4 (0.66 g, 1.05 mmol), zinc powder (0.41 g, 6.31 mmol) and ammonium chloride (0.563 g, 10.5 mmol) were added and the temperature was raised to 26°C for 2 h. When the raw material disappeared, a saturated aqueous solution of sodium bicarbonate, DCM and a small amount of methanol were directly added, extracted twice, dried, and spin-dried to obtain 0.64 g of crude product, which was directly used in the next step.

[0427] Synthesis of Example 35: Compound 5 (0.64 g) and triethylamine (0.33 g, 3.26 mmol) were dissolved in 50 mL of dichloromethane, cooled to 0°C, and then acryloyl chloride (0.126 g, 1.4 mmol) was added dropwise, and the temperature was kept at 0°C for 3 h. After the reaction of the raw materials, dichloromethane and saturated sodium bicarbonate aqueous solution were added, extracted twice, dried, concentrated, and passed through a column to obtain 7 mg of the product. 1 H NMR (400MHz, CDCl3) δ9.80(m,2H),9.04(s,1H),8.76(m,1H),7.96(s,1H),7.32(d,J=8.2Hz,1H),7.15(t,J=7.7Hz,1H),6.93(m,2H), 6.72(s,1H),6.51(dd,J=16.7,2.1Hz,1H),5.77(d,J=11.5Hz,1H),3.94(s,3H),3.89(s,3H),3.14(m,2H),2.73(s,3H),2.60(m,8H).

[0428] Embodiment 36

[0429] The structural formula of the compound used as a kinase inhibitor in this example is:

[0430]

[0431] Synthesis route:

[0432]

[0433] Synthesis of compound 3: Compound 1 (1 g, 3.49 mmol), compound 2 (0.528 g, 4.19 mmol) and DIPEA (1.35 g, 10.46 mmol) were added to N,N-dimethylacetamide and reacted at 80°C for 16 h. After the reaction of the raw materials, water was added and extracted with ethyl acetate three times. The organic phases were combined, washed with brine, dried, concentrated, and passed through a column to obtain 1.2 g of the product.

[0434] Synthesis of compound 4: Compound 3 (1.2 g, 3.06 mmol) and palladium carbon (240 mg, 20%) were added to methanol and reacted at room temperature for 2 h under a hydrogen atmosphere. After the reaction of the raw materials, diatomaceous earth was added for filtration, and the filter cake was washed three times with methanol. The filtrate was combined and concentrated to obtain 1.1 g of crude product.

[0435] Synthesis of compound 5: Compound 4 (1.1 g, 3.04 mmol) and triethylamine (0.92 g, 9.11 mmol) were dissolved in dichloromethane, cooled to 0°C under nitrogen protection, and then a dichloromethane solution of acryloyl chloride (0.329 g, 3.95 mmol) was added dropwise, and the reaction was maintained at 0°C for 2 h. After the reaction of the raw materials, saturated sodium bicarbonate aqueous solution was added, and the dichloromethane was extracted three times. The organic phases were combined, washed with brine, dried, concentrated, and passed through a column to obtain 0.84 g of the product. 1 H NMR (400MHz, CDCl3) δ8.90(s,1H),8.66(s,1H),6.87(s,1H),6.65(s,1H),6.42(dd,J=16.8,1.6Hz,1H),6.30(dd,J=16.8,10.0Hz,1H ),5.69(dd,J=10.0,1.6Hz,1H),3.81(s,3H),3.00-2.86(m,4H),2.82(d,J=9.6Hz,2H),2.66-2.54(m,2H),2.44(s,3H),1.51(m,11H).

[0436] Synthesis of Example 36: Compound 5 (30 mg, 0.072 mmol), compound 6 (23.7 mg, 0.072 mmol) and p-toluenesulfonic acid monohydrate (20.5 mg, 0.11 mmol) were added to a mixed solvent of ethylene glycol methyl ether and N-methylpyrrolidone. Under nitrogen protection, the temperature was raised to 120°C and the reaction was carried out for 6 hours. After the reaction was completed, water and ethyl acetate were added to the reaction system, the aqueous phase was extracted three times, the organic phases were combined, spin-dried, and purified to obtain 9 mg of the product.

[0437] Referring to Example 36, the compounds of Examples 37, 38 and 39 were synthesized as shown in Table 2.

[0438] Table 2 Compounds of Examples 37-39

[0439] Embodiment 40

[0440] The structural formula of the compound used as a kinase inhibitor in this example is:

[0441]

[0442] Synthesis route:

[0443]

[0444] Synthesis of compound 2:

[0445] Compound 1 (3 g, 22.9 mmol, 1 eq) and aluminum chloride (4.56 g, 34.3 mmol, 1.5 eq) were dissolved in dry tetrahydrofuran, heated to 70°C under nitrogen protection and reacted for 1 h, then methyl indole tetrahydrofuran solution (6.45 g, 37.4 mmol, 1.2 eq) was slowly added dropwise under stirring, and the reaction was continued at 70°C for 3 h after the addition was completed, and monitored by TLC. After the reaction of the raw materials, they were cooled to 0°C, slowly added with ice water to quench, extracted with ethyl acetate three times, and the organic phases were combined, dried over anhydrous Na2SO4, and purified by column (petroleum ether / ethyl acetate = 10 / 1) to obtain 3.5 g of compound 2. NMR(400MHz,Chloroform-d)δ8.71(s,1H),8.13-8.06(m,1H),7.88(s,1H),7. 32-7.28(m,1H),7.24(m,2H),5.12(m,1H),3.80(s,3H),1.18(d,J=6.0Hz,6H).

[0446] Synthesis of compound 3:

[0447] Compound 2 (3.5 g, 10.6 mmol, 1 eq) and AZD9291 intermediate (2.96 g, 15.9 mmol, 1.5 eq) were dissolved in dioxane / water, p-toluenesulfonic acid (3.53 g, 18.6 mmol, 1.75 eq) was added under stirring, and then the temperature was raised to 80°C for reaction for 16 h, and TLC was monitored. After the reaction of the raw materials, the reaction system was dried by spin drying, 2N sodium hydroxide aqueous solution was added to adjust the base, and then extracted with ethyl acetate three times, the organic phases were combined, dried over anhydrous Na2SO4, the solvent was dried by spin drying, and 4.1 g of compound 3 was obtained after column purification (dichloromethane / methanol=20 / 1). NMR(400MHz,Chloroform-d)δ9.59(d,J=8.4Hz,1H),8.79(s,1H),7.97(s,2H),7.65(d,J=8.0Hz,1H),7.30(dt,J=8.4,1.2Hz,1H),7.24 -7.19(m,1H),7.12(ddd,J=8.0,7.2,1.2Hz,1H),6.68(d,J=12.0Hz,1H),5.02(m,1H),3.93(s,3H),3.85(s,3H),1.07(d,J=6.0Hz,6H).

[0448] Synthesis of compound 4:

[0449] Compound 3 (557 mg, 1.19 mmol), amine (Compound 3 in Example 18) (224 mg, 1.78 mmol) and DIPEA (307 mg, 2.38 mmol) were added to N,N-dimethylacetamide and reacted at 80°C for 16 h. The reaction solution was poured into ice water, solids were precipitated, filtered (with filter aid), the filter cake was dissolved with dichloromethane, the dichloromethane phase was dried, concentrated, and passed through a column to obtain 230 mg of the product.

[0450] Synthesis of compound 5:

[0451] Compound 4 (230 mg, 0.393 mmol) and palladium carbon (50 mg, 20%) were added to methanol and reacted at room temperature for 2 h under hydrogen atmosphere. After the reaction of the raw materials, diatomaceous earth was added for filtration, and the filter cake was washed three times with methanol. The filtrate was combined and dried to obtain 180 mg of compound 5.

[0452] Synthesis of Example 40:

[0453] Compound 5 (180 mg, 0.324 mmol) and triethylamine (104 mg, 1.03 mmol) were dissolved in dichloromethane, cooled to 0°C under nitrogen protection, and then a dichloromethane solution of acryloyl chloride (36 mg, 0.40 mmol) was added dropwise, and the mixture was kept at 0°C for 2 h. After the reaction of the raw materials, saturated sodium bicarbonate aqueous solution was added, and the mixture was extracted with dichloromethane three times. The organic phases were combined, washed with brine, dried, concentrated, and passed through a column to obtain 5 mg of the product. MS+1: 610.4.

[0454] Referring to Example 40, the compounds of Examples 41, 42, 43, 44, 45, 46 and 47 were synthesized as shown in Table 3.

[0455] Table 3 Compounds of Examples 41-47

[0456] 2. Biological Experiment Section

[0457] 1. Kinase activity detection experiment

[0458] The activity of the compounds prepared in the examples on the EGFR exon 20 insertion mutant kinase was screened at the ATP Km concentration using the kinase activity assay method, and staurosporine and the best active compound (TAK788) disclosed in WO2015195228A1 were used as reference substances. The biological activity screening of the compounds was repeated at 10 concentrations.

[0459]

[0460] 1. Test samples

[0461] Each sample was prepared into a solution with a concentration of 10 mM.

[0462] 2. Experimental methods

[0463] (1) Prepare the basic buffer solution and quenching buffer solution for the kinase used in the experiment

[0464] 20mM Hepes (pH 7.5), 10mM MgCl2, 1mM EGTA, 0.02% Brij35, 0.02mg / ml BSA, 0.1mM Na3VO4, 2mM DTT, 1% DMSO.

[0465] (2) Preparation of compounds for experimental kinases

[0466] Test compounds were dissolved in 100% dimethyl sulfoxide to the specified concentrations. (Serial) dilutions in DMSO were performed using an Integra Viaflo Assist.

[0467] (3) Reaction steps

[0468] The kinase is added to freshly prepared basic reaction buffer and any desired cofactors are added to the substrate solution as above.

[0469] The EGFR exon 20 insertion mutant kinase was added to the substrate solution and gently mixed; the compound in 100% dimethyl sulfoxide was delivered to the kinase reaction mixture using Acoustictechnology (Echo550; nanoliter range) and incubated at room temperature for 20 minutes.

[0470] The reaction was started by adding 33P-ATP (specific activity 10Ci / l) to the reaction mixture, incubated at room temperature for 2 hours, and the radioactivity was detected by the filter-binding method.

[0471] Kinase activity data are expressed as the percentage of kinase activity remaining in the test samples compared to the vehicle (dimethyl sulfoxide) reaction. IC50 values ​​and curve fitting were obtained using Prism (GRAPHPAD software).

[0472] The obtained inhibitory activity IC50 (nM) values ​​of the test samples against EGFR exon 20 insertion mutant kinase are shown in Table 4.

[0473] Table 4 Inhibitory activity of different compounds against EGFR exon 20 insertion mutant kinase (NA: Not active.)

[0474] As can be seen from Table 4, through in vitro biological activity screening, with staurosporine as the reference substance, the compounds used as kinase inhibitors have good inhibitory ability against EGFR exon 20 insertion mutant kinase, and most of them have much higher inhibitory activity than staurosporine. And the activity is comparable to the activity of the best active compound disclosed in WO2015195228A1, but the activity of the compound of our Example 12 is 2-3 times that of the best active compound disclosed in WO2015195228A1. It is very likely to be further developed into a drug for regulating the activity of EGFR exon 20 insertion mutant kinase or treating diseases related to EGFR exon 20 insertion mutant kinase.

[0475] 2. Experimental study on the cell proliferation inhibition activity of EGFR exon 20 insertion mutation:

[0476] 1. Experimental materials:

[0477] RPMI-1640 was purchased from BI.

[0478] Fetal bovine serum was purchased from BI.

[0479] Purchased from Promega.

[0480] Dimethyl sulfoxide (DMSO) was purchased from TCI.

[0481] Ba / F3-FL-EGFR-V769-D770 ins ASV, Ba / F3-FL-EGFR-D77-N771 ins SVD, Ba / F3-FL-EGFR-H773-V774 ins NPH, Ba / F3-FL-EGFR-A763-Y764 ins FQEA and other cells were constructed by Hefei Zhongke Puruisheng Biotechnology Co., Ltd.

[0482] 2. Experimental steps:

[0483] 2.1 Dilution and administration of compounds

[0484] Prepare 1000X compound stock solution with DMSO and dilute with culture medium to 20X final concentration for later use.

[0485] 2.2 Cell seeding

[0486] The cells obtained after centrifugation were suspended with a certain amount of culture medium and counted. The cell suspension was adjusted to a specified density with culture medium, and the diluted cell suspension was taken to a 96-well plate; 5 μl of 20X compound solution was added to each well of the 96-well plate, and the DMSO content in the final system was 0.1%; the 96-well plate was placed in a 37°C, 5% CO2 cell culture incubator and incubated for 72 hours.

[0487] 2.3 Detection

[0488] Before the test, place the 96-well plate at room temperature and add 50 μl of Reagents were added, shaken on a shaker for 2 minutes, and then placed at room temperature for 10 minutes before reading the plate.

[0489] 3. Data Analysis

[0490] The inhibition rate (Inh%) relative to vehicle (DMSO) treated control wells was calculated using the following formula:

[0491] Inhibition rate (Inh%) = 100-(RLU compound-RLU blank) / (RLU control-RLU blank)*100%

[0492] The data were analyzed using GraphPad 7.0 software, and the dose-effect curve was obtained by fitting the data to calculate the IC50 value. Where A < 5 nM, 5 nM ≤ B ≤ 50 nM, C > 50 nM, as shown in Table 5.

[0493] Table 5 Cell proliferation inhibition activity test results of EGFR exon 20 insertion mutations of different compounds

[0494] As can be seen from Table 5, the compounds synthesized by us have good inhibitory ability against EGFR exon 20 insertion mutations. Most of them are much more active than AZD9291. Compared with the activity of TAK-788, most of the compounds of the present invention are more active than it. For example, the activity of our compound (Example 18) is about 2 times that of TAK-788 (see Table 6). It is very likely to be further developed into a drug for regulating the activity of EGFR exon 20 insertion mutations or treating diseases related to EGFR exon 20 insertion mutations.

[0495] Table 6 Comparison of cell proliferation inhibitory activity of different compounds

[0496] 3. Experimental test of cell proliferation inhibition activity of relevant EGFR mutations:

[0497] 1. Experimental materials:

[0498] RPMI was purchased from Nanjing Shenghang.

[0499] WST-8 was purchased from Jinrui Meixiang.

[0500] Dimethyl sulfoxide (DMSO) was purchased from Aike.

[0501] Ba / F3 (EGFRdel19 / L858R / C797S) was purchased from Kangyuan Broadcom.

[0502] PC9 (EGFRdel19) and H-1975 (EGFRL858R / T790M) cells were purchased from Beina Pharmaceuticals.

[0503] 2. Experimental steps:

[0504] Cell culture medium: RPMI containing 10% fetal bovine serum, 5 mM HEPES and 2 mM glutamine.

[0505] The cell suspensions of Ba / F3 (EGFRdel19 / L858R / C797S), PC9 (EGFRdel19) and H-1975 (EGFRL858R / T790M) were diluted to 5000 cells / 80 μl, 1500 cells / 80 μl and 4000 cells / 80 μl, respectively. 80 μl / well was added to a 96-well culture plate and incubated overnight in an incubator at 37°C filled with 5% carbon dioxide.

[0506] The compound was diluted to the desired concentration in culture medium at five times the final concentration. 20 μl of the compound dilution was transferred to the culture plate containing 80 μl of the above overnight incubated cells and cultured for another 72 hours.

[0507] After 72 hours, 10 μl of 6 mg / ml WST8 solution dissolved in phosphate buffer was added and incubated for 3 hours at 37°C and 5% carbon dioxide. The light absorbance at 450 nm was read and the absorbance at 650 nm was subtracted.

[0508] The obtained light absorption value was used to calculate the cell survival rate according to the following formula:

[0509] Cell survival rate % = (OD measured value / OD drug-free cells) X 100

[0510] The IC50 of % cell viability corresponding to the compound concentration was calculated using Prizm8.2 software. The results are shown in Table 7.

[0511] Table 7 Cell proliferation inhibition activity experiments related to EGFR mutations <![CDATA[Cell line / IC 50 (nM)]]> TAK-788 AZD-9291 Embodiment 18 H-1975(EGFRL858 / T790M) 101.4 20.19 91.16 PC-9 (EGFRdel19) 24.05 7.846 6.612 Ba / F3(EGFRdel19 / L858 / 797s) 2627 2704 3977

[0512] As can be seen from Table 7, the cell inhibitory activity of Example 18 on H-1975 (EGFRL858 / T790M) and C-9 (EGFRdel19) is not much different from that of osimertinib, and is better than TAK788. Therefore, our compounds also have a certain therapeutic effect on the treatment of related diseases caused by EGFR mutations.

Claims

1. A compound for use as a kinase inhibitor, characterized in that A compound of the following structural formula or a pharmaceutically acceptable salt thereof:

2. Use of the compound used as a kinase inhibitor as claimed in claim 1 in the preparation of a medicament for treating diseases related to EGFR mutation and / or Her2 mutation.

3. The use according to claim 2, characterized in that: The EGFR mutation and / or Her2 mutation is an exon 20 insertion mutation, an EGFR exon 19 deletion, and an EGFR exon 21 L858R point mutation.

Citation Information

Patent Citations

  • Heteroaryl compounds for kinase inhibition

    WO2015195228A1